U.S. patent application number 13/872793 was filed with the patent office on 2013-11-07 for vaccines based on targeting antigen to dcir expressed on antigen-presenting cells.
The applicant listed for this patent is Baylor Research Institute. Invention is credited to Jacques F. Banchereau, Anne-Laure Flamar, Eynav Klechevsky, Gerard Zurawski, Sandra Zurawski.
Application Number | 20130295120 13/872793 |
Document ID | / |
Family ID | 39682352 |
Filed Date | 2013-11-07 |
United States Patent
Application |
20130295120 |
Kind Code |
A1 |
Zurawski; Gerard ; et
al. |
November 7, 2013 |
VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED ON
ANTIGEN-PRESENTING CELLS
Abstract
The present invention includes compositions and methods for
increasing the effectiveness of antigen presentation using a
DCIR-specific antibody or fragment thereof to which an antigen is
attached that forms an antibody-antigen complex, wherein the
antigen is processed and presented by a dendritic cell that has
been contacted with the antibody-antigen complex.
Inventors: |
Zurawski; Gerard;
(Midlothian, TX) ; Banchereau; Jacques F.;
(Montclair, NJ) ; Klechevsky; Eynav; (Haifa,
IL) ; Zurawski; Sandra; (Midlothian, TX) ;
Flamar; Anne-Laure; (Dallas, TX) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Baylor Research Institute; |
|
|
US |
|
|
Family ID: |
39682352 |
Appl. No.: |
13/872793 |
Filed: |
April 29, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13234914 |
Sep 16, 2011 |
8449888 |
|
|
13872793 |
|
|
|
|
12024897 |
Feb 1, 2008 |
8057798 |
|
|
13234914 |
|
|
|
|
60888032 |
Feb 2, 2007 |
|
|
|
Current U.S.
Class: |
424/178.1 ;
435/377 |
Current CPC
Class: |
A61K 47/6901 20170801;
A61K 2039/505 20130101; A61K 39/02 20130101; A61P 37/00 20180101;
B82Y 5/00 20130101; C12N 2760/16134 20130101; A61K 2039/6056
20130101; C07K 16/2851 20130101; A61K 47/6897 20170801; C12N 5/0639
20130101; A61K 39/145 20130101; A61K 39/21 20130101; A61K 39/12
20130101; A61P 31/10 20180101; A61P 35/00 20180101; A61P 33/02
20180101; A61P 37/04 20180101; A61P 31/04 20180101; A61P 31/12
20180101 |
Class at
Publication: |
424/178.1 ;
435/377 |
International
Class: |
C07K 16/28 20060101
C07K016/28; C12N 5/0784 20060101 C12N005/0784 |
Goverment Interests
STATEMENT OF FEDERALLY FUNDED RESEARCH
[0002] This invention was made with U.S. Government support under
Contract No. 1U19A1057234-0100003 awarded by the NIH. The
government has certain rights in this invention.
Claims
1-25. (canceled)
26. A method for eliciting an immune response against an antigen
comprising contacting antigen presenting cells with a composition
comprising an antibody-antigen complex having a Dendritic Cell
Immunoreceptor (DCIR)-specific antibody, or fragment thereof,
attached to an antigen, wherein an immune response against the
antigen is elicited.
27. The method of claim 26, wherein DCIR-specific antibody or
fragment thereof is bound to one half of a Cohesin/Dockerin
pair.
28. The method of claim 26, wherein DCIR-specific antibody or
fragment thereof is bound to one half of a Cohesin/Dockerin pair
and the antigen is bound to the complementary half of the
Cohesin/Dockerin pair to form the complex.
29. The method of claim 26, wherein the antigen is a bacterial,
viral, fungal, or protozoan antigen.
30. The method of claim 26, wherein the composition further
comprises an adjuvant.
31. The method of claim 26, wherein the antigen presenting cells
are dendritic cells.
32. The method of claim 26, wherein the antigen presenting cells
are contacted with the composition by administering the composition
to a patient.
33. A method for eliciting an immune response against an antigen
comprising contacting dendritic cells with a composition comprising
an antibody-antigen complex having a Dendritic Cell Immunoreceptor
(DCIR)-specific antibody, or fragment thereof, attached to an
antigen through Cohesin/Dockerin pair, wherein an immune response
against the antigen is elicited.
34. The method of claim 35, wherein the antigen is a bacterial,
viral, fungal, or protozoan antigen.
35. The method of claim 35, wherein the composition further
comprises an adjuvant.
36. The method of claim 26, wherein the antigen presenting cells
are contacted with the composition by administering the composition
to a patient.
37. A method for eliciting an immune response against an antigen in
a patient comprising administering to the patient a composition
comprising an antibody-antigen complex having a Dendritic Cell
Immunoreceptor (DCIR)-specific antibody, or fragment thereof,
attached to an antigen, wherein an immune response against the
antigen is elicited in the patient.
38. The method of claim 39, wherein DCIR-specific antibody or
fragment thereof is bound to one half of a Cohesin/Dockerin
pair.
39. The method of claim 39, wherein DCIR-specific antibody or
fragment thereof is bound to one half of a Cohesin/Dockerin pair
and the antigen is bound to the complementary half of the
Cohesin/Dockerin pair to form the complex.
40. The method of claim 39, wherein the antigen is a bacterial,
viral, fungal, or protozoan antigen.
41. The method of claim 39, wherein the composition further
comprises an adjuvant.
42. The method of claim 39, further comprising administering an
adjuvant to the patient with the composition.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Continuation of U.S. patent
application Ser. No. 12/024,897, filed Feb. 1, 2008, now U.S. Pat.
No. ______, issued ______, which claims priority to U.S.
Provisional Application Ser. No. 60/888,032, filed Feb. 2, 2007,
the contents of which are incorporated by reference herein in their
entirety.
TECHNICAL FIELD OF THE INVENTION
[0003] The present invention relates in general to the field of
vaccination, and more particularly, to vaccines based on targeting
antigen to DCIR expressed on antigen-presenting cells.
BACKGROUND OF THE INVENTION
[0004] Without limiting the scope of the invention, its background
is described in connection with antigen presentation.
[0005] Human vaccines based on dendritic cell (DC)-targeting are a
new concept that rests on compelling studies in mouse models. Here,
small doses of relatively weak antigens carried to DC by antibodies
directed to certain DC receptors can elicit potent and broad immune
responses. To develop such vaccines for humans needs a better
understanding of exactly which DC receptor should be used for this
antigen-targeting application. This is because there is not always
exact correspondence between the muse and human immune systems, and
also because not all potential DC receptors have been examined
carefully for this vaccine application.
[0006] Thus, studies that in vitro test various anti-human DC
receptor targets have been initiated, for example, DCs targeted
with melanoma antigen pmel17 fused to a human mAb against mannose
receptor activated T cells in the context of HLA class I and class
II molecules (Ramakrishna, Treml et al. 2004). Also, targeting the
model antigen KLH to DCs via a humanized anti-DC-SIGN mAb
effectively induced antigen-specific naive as well as dose-sparing
recall T cell responses (Tacken, de Vries et al. 2005). Besides
mannose receptor and DC-SIGN, human DCs express other receptors
known to be involved in antigen capture. Many of these are C-type
lectin receptors (CLRs) including LOX-1, DEC205, DC-ASGPR,
Langerin, DCIR, BDCA-2, DECTIN-1, and CLEC-6. These CLRs are
differently expressed by distinct subsets of DC and their
expression can vary with the state of DC maturation (Figdor, van
Kooyk et al. 2002; Geijtenbeek, van Vliet et al. 2004).
[0007] DC subsets stimulate distinct immune responses, and
therefore, targeting antigen to these subsets via differentially
expressed receptor should elicit different immune responses
(Shortman and Liu 2002). Furthermore, different receptors on the
same DC subset may direct the antigen to separate processing
pathways (Trombetta and Mellman 2005). Lastly, some of these
receptors are not intrinsically activating (e.g., DEC205 (Bonifaz,
Bonnyay et al. 2004)), while others may be activating (e.g., LOX-1
(Delneste, Magistrelli et al. 2002)) or have not been studied
thoroughly. The importance of DC-activation concomitant with
antigen uptake is not known. But if this is beneficial, the
DC-activation via the targeting mAb would simplify formulation of
targeting vaccines.
SUMMARY OF THE INVENTION
[0008] In the context of these considerations, the present
inventors have recognized an urgent need for a systematic
comparison to define the most appropriate human DC-targeting
receptors for desired immune outcomes by exploring in detail in
vitro, CD4.sup.+ and CD8.sup.+ T cell naive and recall responses.
This application describes the special and unexpected
characteristics of a particular DC receptor--Dendritic Cell
Inhibitory Receptor (DCIR)--which show it to be an ideal receptor
for the purpose of targeting antigens to human DCs for preventative
and therapeutic vaccination.
[0009] The present invention includes compositions and methods for
making and using vaccine that specifically target (deliver)
antigens to antigen-presenting cells for the purpose of eliciting
potent and broad immune responses directed against the antigen. The
purpose is primarily to evoke protective or therapeutic immune
responses against the agent (pathogen or cancer) from which the
antigen was derived.
[0010] More particularly, the present invention includes
compositions, methods and methods for designing and making target
specific a single recombinant antibody (mAb) that carries one or
more antigens in a controlled modular structure, activating
proteins, or other antibodies. The modular rAb carrier of the
present invention can be used, e.g., to target (via one primary
recombinant antibody against an internalizing human dendritic cell
receptor) multiple antigens and/or antigens and an activating
cytokine to dendritic cells (DC). Also, the invention also provides
a way of joining two different recombinant mAbs end-to-end in a
controlled and defined manner.
[0011] The present invention includes compositions and methods for
increasing the effectiveness of antigen presentation by a
DCIR-expressing antigen presenting cell by isolating and purifying
a DCIR-specific antibody or fragment thereof to which a targeted
agent is attached that forms an antibody-antigen complex, wherein
the agent is processed and presented by, e.g., a dendritic cell,
that has been contacted with the antibody-agent complex. In one
embodiment, the antigen presenting cell is a dendritic cell and the
DCIR-specific antibody or fragment thereof is bound to one half of
a Coherin/Dockerin pair. The DCIR-specific antibody or fragment
thereof may also be bound to one half of a Coherin/Dockerin pair
and an antigen is bound to the complementary half of the
Coherin/Dockerin pair to form a complex. Non-limiting examples
agents include one or more peptides, proteins, lipids,
carbohydrates, nucleic acids and combinations thereof.
[0012] The agent may one or more cytokine selected from
interleukins, transforming growth factors (TGFs), fibroblast growth
factors (FGFs), platelet derived growth factors (PDGFs), epidermal
growth factors (EGFs), connective tissue activated peptides
(CTAPs), osteogenic factors, and biologically active analogs,
fragments, and derivatives of such growth factors, B/T-cell
differentiation factors, B/T-cell growth factors, mitogenic
cytokines, chemotactic cytokines, colony stimulating factors,
angiogenesis factors, IFN-.alpha., IFN-.beta., IFN-.gamma., IL1,
IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL11, IL12, IL13,
IL14, IL15, IL16, IL17, IL18, etc., leptin, myostatin, macrophage
stimulating protein, platelet-derived growth factor, TNF-.alpha.,
TNF-.beta., NGF, CD40L, CD137L/4-1BBL, human lymphotoxin-.beta.,
G-CSF, M-CSF, GM-CSF, PDGF, IL-1.alpha., IL1-.beta., IP-10, PF4,
GRO, 9E3, erythropoietin, endostatin, angiostatin, VEGF,
transforming growth factor (TGF) supergene family include the beta
transforming growth factors (for example TGF-.beta.1, TGF-.beta.2,
TGF-.beta.3); bone morphogenetic proteins (for example, BMP-1,
BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9);
heparin-binding growth factors (fibroblast growth factor (FGF),
epidermal growth factor (EGF), platelet-derived growth factor
(PDGF), insulin-like growth factor (IGF)); Inhibins (for example,
Inhibin A, Inhibin B); growth differentiating factors (for example,
GDF-1); and Activins (for example, Activin A, Activin B, Activin
AB). In another embodiment, the agent comprises an antigen that is
a bacterial, viral, fungal, protozoan or cancer protein.
[0013] The present invention also includes compositions and methods
for increasing the effectiveness of antigen presentation by
dendritic cells comprising binding a DCIR-specific antibody or
fragment thereof to which an antigen is attached that forms an
antibody-antigen complex, wherein the antigen is processed and
presented by a dendritic cell that has been contacted with the
antibody-antigen complex. Another embodiment is the use of
antibodies or other specific binding molecules directed to DCIR for
delivering antigens to antigen-presenting cells for the purpose of
eliciting protective or therapeutic immune responses. The use of
antigen-targeting reagents specific to DCIR for vaccination via the
skin; antigen-targeting reagents specific to DCIR in association
with co-administered or linked adjuvant for vaccination or use for
antigen-targeting (vaccination) purposes of specific antigens which
can be expressed as recombinant antigen-antibody fusion
proteins.
[0014] Another embodiment includes a method for increasing the
effectiveness of dendritic cells by isolating patient dendritic
cells; exposing the dendritic cells to activating amounts of
anti-DCIR antibodies or fragments thereof and antigen to form
antigen-loaded, activated dendritic cells; and reintroducing the
antigen-loaded, activated dendritic cells into the patient. The
antigen may be a bacterial, viral, fungal, protozoan or cancer
protein. The present invention also includes an anti-DCIR
immunoglobulin or portion thereof that is secreted from mammalian
cells and an antigen bound to the immunoglobulin. The
immunoglobulin is bound to one half of a cohesin/dockerin domain,
or it may also include a complementary half of the cohesin-dockerin
binding pair bound to an antigen that forms a complex with the
modular rAb carrier, or a complementary half of the
cohesin-dockerin binding pair that is a fusion protein with an
antigen. The antigen specific domain may be a full length antibody,
an antibody variable region domain, an Fab fragment, a Fab'
fragment, an F(ab).sub.2 fragment, and Fv fragment, and Fabc
fragment and/or a Fab fragment with portions of the Fc domain. The
anti-DCIR immunoglobulin may also be bound to a toxin selected from
wherein the toxin is selected from the group consisting of a
radioactive isotope, metal, enzyme, botulin, tetanus, ricin,
cholera, diphtheria, aflatoxins, perfringens toxin, mycotoxins,
shigatoxin, staphylococcal enterotoxin B, T2, seguitoxin,
saxitoxin, abrin, cyanoginosin, alphatoxin, tetrodotoxin,
aconotoxin, snake venom and spider venom. The antigen may be a
fusion protein with the immunoglobulin or bound chemically
covalently or not.
[0015] Another embodiment is a vaccine with a DCIR-specific
antibody or fragment thereof to which an antigen is attached that
forms an antibody-antigen complex, wherein the antigen is processed
and presented by a dendritic cell that has been contacted with the
antibody-antigen complex.
[0016] The novel antibodies of the present invention were also able
to show novel tissue distribution information. Due to their
specific affinity, it was found the anti-DCIR antibodies of the
present invention binding monkey DCIR, and are effective for using
anti-DCIR-Flu m1 targeting for expanding Flu m1-specific CD8 cells
in vivo [hu-mouse], and in vitro targeting of ex vivo human skin
cells. Furthermore, it was found that a complex of carbohydrate
ligands for DCIR can be used as surrogates for anti-DCIR agents for
antigen delivery. Therefore, another embodiment of the present
invention is a T cell antigen that includes an antigenic T cell
epitope peptide bound to at least a portion of a glycan that
includes
Neu5Ac.alpha.2-3Gal.beta.1-4GlcNAc.beta.1-2Man.alpha.1-3(Neu5Ac.-
alpha.2-3Gal.beta.1-4GlcNAc.beta.1-2Man.alpha.1-6)Man.beta.1-4GlcNAc.beta.-
1-4GlcNAc.beta.-Sp12 that binds specifically to DCIR. The glycan
(and derivatives thereof) can also be used alone or in combination
to block DCIR binding.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] For a more complete understanding of the features and
advantages of the present invention, reference is now made to the
detailed description of the invention along with the accompanying
figures and in which:
[0018] FIG. 1 shows that many, but not all, hybridoma supernatants
elicited specific production of MCP-1 when compared to controls,
namely mAbs 4C7, 9E8, 19E3, 1G3, 10A5, 29G10, 3C2, 3G2, 24A5, 30F3,
12E2, 5F9, 2F11, 24E7,31A6, 6A11,2 9E9, 2H8, 30D9, 6C8, 35F1, 3F12
were selected for further characterization;
[0019] FIG. 2 shows the high affinity interaction of the mAbs with
DCIR bound to plate by ELISA;
[0020] FIG. 3 shows the binding of the high affinity antibodies for
use in FACS;
[0021] FIG. 4 shows that DCIR is also expressed on three human DC
subtypes isolated directly from human skin;
[0022] FIG. 5 shows DCIR-specific staining of a population of cells
surrounding a germinal center within a human tonsil;
[0023] FIG. 6 shows an example of the cross-Flu M1 protein and the
mAb to DCIR;
[0024] FIG. 7 shows the cross-linking of Coh.Flu M1 to
Anti-DCIR.sub.--2C9 mAb;
[0025] FIG. 8 shows that Flu M1 cross-linked to anti-DCIR mAb
induces the expansion of Flu M1-specific CD8+ T cells more
efficiently than Flu M1 protein unlinked to mAb;
[0026] FIG. 9 shows that Flu M1 cross-linked to anti-DCIR mAb
induces the expansion of Flu M1-specific CD8+ T cells more
efficiently via LCs than Int-DCs;
[0027] FIG. 10 shows such H+L chain vectors encoding chimeric
mouse-human rAbs corresponding to a number of different anti-DCIR
mAbs co-transfected into 293 cells and assayed by anti-human FC
ELISA for secretion of rAb into the culture supernatant;
[0028] FIG. 11 shows that Coh.Flu M1 linked to anti-DCIR.Doc rAb
binds specifically to GM/IL-15 human DC;
[0029] FIG. 12 shows that the Coh.Flu M1 linked to
anti-DC-SIGN/L.Doc or anti-DCIR.Doc rAb binds and is internalized
into to GM-CSF/IL-4 human DC;
[0030] FIG. 13 shows that the Anti-DCIR.Doc:Coh.Flu complex is more
efficient at expanding Flu M1-specific CD8+ T cells than other
[anti-DC receptor rAbs.Doc:Coh.Flu M1] complexes;
[0031] FIG. 14 shows that the Anti-DCIR.Doc:Coh.Flu complex
administered for 1 day is more efficient at expanding Flu
M1-specific CD8+ T cells than other [anti-DC receptor
rAbs.Doc:Coh.Flu M1] complexes;
[0032] FIG. 15 shows that various antigens expressed as fusions to
the C-terminus of rAb H chain have intrinsic effects on the
secretion of rAb.antigen;
[0033] FIG. 16 shows the Anti-DCIR.Flu HA5 rAbs are secreted at
various efficiencies depending on the nature of the variable
regions;
[0034] FIG. 17 shows that Anti-DCIR mAb enhances priming of HIV
antigen-specific CD8+ cells;
[0035] FIG. 18 shows the Anti-DCIR mAb enhances priming of HIV
antigen-specific CD8+ cells;
[0036] FIG. 19 shows immunohistochemistry analysis of DCIR
distribution in human epithelial sheet;
[0037] FIGS. 20A-20D shows monoclonal antibodies to DCIR Antigen,
specifically, affinity to DCIR;
[0038] FIG. 21 shows the cross-reactivity of anti-DCIR mAbs to
Rhesus macaque DCIR;
[0039] FIG. 22 is a graph that shows the binding of DCIR ectodomain
to specific glycan structures;
[0040] FIG. 23A to 23C show that DCIR is a global target for all
blood DC subsets; and
[0041] FIG. 24 shows that demonstrate that vaccination with
DCIR-FluM1 permits generation of FluM1 specific recall CD8+ T cell
immunity.
DETAILED DESCRIPTION OF THE INVENTION
[0042] While the making and using of various embodiments of the
present invention are discussed in detail below, it should be
appreciated that the present invention provides many applicable
inventive concepts that can be embodied in a wide variety of
specific contexts. The specific embodiments discussed herein are
merely illustrative of specific ways to make and use the invention
and do not delimit the scope of the invention.
[0043] To facilitate the understanding of this invention, a number
of terms are defined below. Terms defined herein have meanings as
commonly understood by a person of ordinary skill in the areas
relevant to the present invention. Terms such as "a", "an" and
"the" are not intended to refer to only a singular entity, but
include the general class of which a specific example may be used
for illustration. The terminology herein is used to describe
specific embodiments of the invention, but their usage does not
delimit the invention, except as outlined in the claims.
[0044] Dendritic cells (DCs) are antigen-presenting cells that play
a key role in regulating antigen-specific immunity (Mellman and
Steinman 2001), (Banchereau, Briere et al. 2000), (Cella, Sallusto
et al. 1997). DCs capture antigens, process them into peptides, and
present these to T cells. Therefore delivering antigens directly to
DC is a focus area for improving vaccines. One such example is the
development of DC-based vaccines using ex-vivo antigen-loading of
autologous DCs that are then re-administrated to patients
(Banchereau, Schuler-Thurner et al. 2001), (Steinman and Dhodapkar
2001). Another strategy to improve vaccine efficacy is specific
targeting to DC of antigen conjugated to antibodies against
internalizing DC-specific receptors. The potential of targeting
DCfor vaccination is highlighted by key mouse studies. In vivo,
targeting with an anti-LOX-1 mAb coupled to ovalbumin (OVA) induced
a protective CD8+ T cell response, via exogenous antigen
cross-presentation toward the MHC class I pathway (Delneste,
Magistrelli et al. 2002). Also, OVA conjugated to anti-DEC205 mAb
in combination with a CD40L maturation stimulus enhanced the MHC
class I-restricted presentation by DCs in vivo and led to the
durable formation of effector memory CD8+ T cells (Bonifaz, Bonnyay
et al. 2004). Both these studies showed dramatic dose-sparing
(i.e., strong immune-responses at very low antigen doses) and
suggested broader responses than normally seen with other types of
OVA immunization. Recent work with targeting of HIV gag antigen to
DC via DEC205 has extended these concepts to a clinically relevant
antigen and confirmed the tenents of targeting antigen to
DC--dramatic dose-sparing, protective responses from a single
vaccination, and expansion of antigen-specific T cells in both the
CD8 and CD4 compartments (Trumpfheller, Finke et al. 2006).
[0045] The present invention provides for the complexing of
multiple antigens or proteins (engineered, expressed, and purified
independently from the primary mAb) in a controlled, multivariable
fashion, to one single primary recombinant mAb. Presently, there
are methods for engineering site-specific biotinylation sites that
provide for the addition of different proteins (each engineered
separately linked to streptavidin) to the one primary mAb. However,
the present invention provides for addition to the primary mAb of
multiple combinations, in fixed equimolar ratios and locations, of
separately engineered proteins.
[0046] As used herein, the term "modular rAb carrier" is used to
describe a recombinant antibody system that has been engineered to
provide the controlled modular addition of diverse antigens,
activating proteins, or other antibodies to a single recombinant
monoclonal antibody (mAb). The rAb may be a monoclonal antibody
made using standard hybridoma techniques, recombinant antibody
display, humanized monoclonal antibodies and the like. The modular
rAb carrier can be used to, e.g., target (via one primary
recombinant antibody against an internalizing receptor, e.g., a
human dendritic cell receptor) multiple antigens and/or antigens
and an activating cytokine to dendritic cells (DC). The modular rAb
carrier may also be used to join two different recombinant mAbs
end-to-end in a controlled and defined manner.
[0047] The antigen binding portion of the "modular rAb carrier" may
be one or more variable domains, one or more variable and the first
constant domain, an Fab fragment, a Fab' fragment, an F(ab).sub.2
fragment, and Fv fragment, and Fabc fragment and/or a Fab fragment
with portions of the Fc domain to which the cognate modular binding
portions are added to the amino acid sequence and/or bound. The
antibody for use in the modular rAb carrier can be of any isotype
or class, subclass or from any source (animal and/or
recombinant).
[0048] In one non-limiting example, the modular rAb carrier is
engineered to have one or more modular cohesin-dockerin protein
domains for making specific and defined protein complexes in the
context of engineered recombinant mAbs. The mAb is a portion of a
fusion protein that includes one or more modular cohesin-dockerin
protein domains carboxy from the antigen binding domains of the
mAb. The cohesin-dockerin protein domains may even be attached
post-translationally, e.g., by using chemical cross-linkers and/or
disulfide bonding.
[0049] The term "antigen" as used herein refers to a molecule that
can initiate a humoral and/or cellular immune response in a
recipient of the antigen. Antigen may be used in two different
contexts with the present invention: as a target for the antibody
or other antigen recognition domain of the rAb or as the molecule
that is carried to and/or into a cell or target by the rAb as part
of a dockerin/cohesin-molecule complement to the modular rAb
carrier. The antigen is usually an agent that causes a disease for
which a vaccination would be advantageous treatment. When the
antigen is presented on MHC, the peptide is often about 8 to about
25 amino acids. Antigens include any type of biologic molecule,
including, for example, simple intermediary metabolites, sugars,
lipids and hormones as well as macromolecules such as complex
carbohydrates, phospholipids, nucleic acids and proteins. Common
categories of antigens include, but are not limited to, viral
antigens, bacterial antigens, fungal antigens, protozoal and other
parasitic antigens, tumor antigens, antigens involved in autoimmune
disease, allergy and graft rejection, and other miscellaneous
antigens.
[0050] The modular rAb carrier is able to carry any number of
active agents, e.g., antibiotics, anti-infective agents, antiviral
agents, anti-tumoral agents, antipyretics, analgesics,
anti-inflammatory agents, therapeutic agents for osteoporosis,
enzymes, cytokines, anticoagulants, polysaccharides, collagen,
cells, and combinations of two or more of the foregoing active
agents. Examples of antibiotics for delivery using the present
invention include, without limitation, tetracycline,
aminoglycosides, penicillins, cephalosporins, sulfonamide drugs,
chloramphenicol sodium succinate, erythromycin, vancomycin,
lincomycin, clindamycin, nystatin, amphotericin B, amantadine,
idoxuridine, p-amino salicyclic acid, isoniazid, rifampin,
antinomycin D, mithramycin, daunomycin, adriamycin, bleomycin,
vinblastine, vincristine, procarbazine, imidazole carboxamide, and
the like.
[0051] Examples of anti-tumor agents for delivery using the present
invention include, without limitation, doxorubicin, Daunorubicin,
taxol, methotrexate, and the like. Examples of antipyretics and
analgesics include aspirin, Motrin.RTM., Ibuprofen.RTM., naprosyn,
acetaminophen, and the like.
[0052] Examples of anti-inflammatory agents for delivery using the
present invention include, without limitation, include NSAIDS,
aspirin, steroids, dexamethasone, hydrocortisone, prednisolone,
Diclofenac Na, and the like.
[0053] Examples of therapeutic agents for treating osteoporosis and
other factors acting on bone and skeleton include for delivery
using the present invention include, without limitation, calcium,
alendronate, bone GLa peptide, parathyroid hormone and its active
fragments, histone H4-related bone formation and proliferation
peptide and mutations, derivatives and analogs thereof.
[0054] Examples of enzymes and enzyme cofactors for delivery using
the present invention include, without limitation, pancrease,
L-asparaginase, hyaluronidase, chymotrypsin, trypsin, tPA,
streptokinase, urokinase, pancreatin, collagenase, trypsinogen,
chymotrypsinogen, plasminogen, streptokinase, adenyl cyclase,
superoxide dismutase (SOD), and the like.
[0055] Examples of cytokines for delivery using the present
invention include, without limitation, interleukins, transforming
growth factors (TGFs), fibroblast growth factors (FGFs), platelet
derived growth factors (PDGFs), epidermal growth factors (EGFs),
connective tissue activated peptides (CTAPs), osteogenic factors,
and biologically active analogs, fragments, and derivatives of such
growth factors. Cytokines may be B/T-cell differentiation factors,
B/T-cell growth factors, mitogenic cytokines, chemotactic
cytokines, colony stimulating factors, angiogenesis factors,
IFN-.alpha., IFN-.beta., IFN-.gamma., IL1, IL2, IL3, IL4, IL5, IL6,
IL7, IL8, IL9, IL10, IL11, IL12, IL13, IL14, IL15, IL16, IL17,
IL18, etc., leptin, myostatin, macrophage stimulating protein,
platelet-derived growth factor, TNF-.alpha., TNF-.beta., NGF,
CD40L, CD137L/4-1BBL, human lymphotoxin-.beta., G-CSF, M-CSF,
GM-CSF, PDGF, IL-1.alpha., IL1-.beta., IP-10, PF4, GRO, 9E3,
erythropoietin, endostatin, angiostatin, VEGF or any fragments or
combinations thereof. Other cytokines include members of the
transforming growth factor (TGF) supergene family include the beta
transforming growth factors (for example TGF-.beta.1, TGF-.beta.2,
TGF-.beta.3); bone morphogenetic proteins (for example, BMP-1,
BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9);
heparin-binding growth factors (for example, fibroblast growth
factor (FGF), epidermal growth factor (EGF), platelet-derived
growth factor (PDGF), insulin-like growth factor (IGF)); Inhibins
(for example, Inhibin A, Inhibin B); growth differentiating factors
(for example, GDF-1); and Activins (for example, Activin A, Activin
B, Activin AB).
[0056] Examples of growth factors for delivery using the present
invention include, without limitation, growth factors that can be
isolated from native or natural sources, such as from mammalian
cells, or can be prepared synthetically, such as by recombinant DNA
techniques or by various chemical processes. In addition, analogs,
fragments, or derivatives of these factors can be used, provided
that they exhibit at least some of the biological activity of the
native molecule. For example, analogs can be prepared by expression
of genes altered by site-specific mutagenesis or other genetic
engineering techniques.
[0057] Examples of anticoagulants for delivery using the present
invention include, without limitation, include warfarin, heparin,
Hirudin, and the like. Examples of factors acting on the immune
system include for delivery using the present invention include,
without limitation, factors which control inflammation and
malignant neoplasms and factors which attack infective
microorganisms, such as chemotactic peptides and bradykinins.
[0058] Examples of viral antigens include, but are not limited to,
e.g., retroviral antigens such as retroviral antigens from the
human immunodeficiency virus (HIV) antigens such as gene products
of the gag, pol, and env genes, the Nef protein, reverse
transcriptase, and other HIV components; hepatitis viral antigens
such as the S, M, and L proteins of hepatitis B virus, the pre-S
antigen of hepatitis B virus, and other hepatitis, e.g., hepatitis
A, B, and C, viral components such as hepatitis C viral RNA;
influenza viral antigens such as hemagglutinin and neuraminidase
and other influenza viral components; measles viral antigens such
as the measles virus fusion protein and other measles virus
components; rubella viral antigens such as proteins E1 and E2 and
other rubella virus components; rotaviral antigens such as VP7sc
and other rotaviral components; cytomegaloviral antigens such as
envelope glycoprotein B and other cytomegaloviral antigen
components; respiratory syncytial viral antigens such as the RSV
fusion protein, the M2 protein and other respiratory syncytial
viral antigen components; herpes simplex viral antigens such as
immediate early proteins, glycoprotein D, and other herpes simplex
viral antigen components; varicella zoster viral antigens such as
gpl, gpII, and other varicella zoster viral antigen components;
Japanese encephalitis viral antigens such as proteins E, M-E,
M-E-NS1, NS1, NS1-NS2A, 80% E, and other Japanese encephalitis
viral antigen components; rabies viral antigens such as rabies
glycoprotein, rabies nucleoprotein and other rabies viral antigen
components. See Fundamental Virology, Second Edition, eds. Fields,
B. N. and Knipe, D. M. (Raven Press, New York, 1991) for additional
examples of viral antigens.
[0059] Antigenic targets that may be delivered using the
rAb-DC/DC-antigen vaccines of the present invention include genes
encoding antigens such as viral antigens, bacterial antigens,
fungal antigens or parasitic antigens. Viruses include
picornavirus, coronavirus, togavirus, flavirvirus, rhabdovirus,
paramyxovirus, orthomyxovirus, bunyavirus, arenavirus, reovirus,
retrovirus, papilomavirus, parvovirus, herpesvirus, poxvirus,
hepadnavirus, and spongiform virus. Other viral targets include
influenza, herpes simplex virus 1 and 2, measles, dengue, smallpox,
polio or HIV. Pathogens include trypanosomes, tapeworms,
roundworms, helminthes, malaria. Tumor markers, such as fetal
antigen or prostate specific antigen, may be targeted in this
manner. Other examples include: HIV env proteins and hepatitis B
surface antigen. Administration of a vector according to the
present invention for vaccination purposes would require that the
vector-associated antigens be sufficiently non-immunogenic to
enable long term expression of the transgene, for which a strong
immune response would be desired. In some cases, vaccination of an
individual may only be required infrequently, such as yearly or
biennially, and provide long term immunologic protection against
the infectious agent. Specific examples of organisms, allergens and
nucleic and amino sequences for use in vectors and ultimately as
antigens with the present invention may be found in U.S. Pat. No.
6,541,011, relevant portions incorporated herein by reference, in
particular, the tables that match organisms and specific sequences
that may be used with the present invention.
[0060] Bacterial antigens for use with the rAb vaccine disclosed
herein include, but are not limited to, e.g., bacterial antigens
such as pertussis toxin, filamentous hemagglutinin, pertactin,
FIM2, FIM3, adenylate cyclase and other pertussis bacterial antigen
components; diptheria bacterial antigens such as diptheria toxin or
toxoid and other diptheria bacterial antigen components; tetanus
bacterial antigens such as tetanus toxin or toxoid and other
tetanus bacterial antigen components; streptococcal bacterial
antigens such as M proteins and other streptococcal bacterial
antigen components; gram-negative bacilli bacterial antigens such
as lipopolysaccharides and other gram-negative bacterial antigen
components, Mycobacterium tuberculosis bacterial antigens such as
mycolic acid, heat shock protein 65 (HSP65), the 30 kDa major
secreted protein, antigen 85A and other mycobacterial antigen
components; Helicobacter pylori bacterial antigen components;
pneumococcal bacterial antigens such as pneumolysin, pneumococcal
capsular polysaccharides and other pneumococcal bacterial antigen
components; haemophilus influenza bacterial antigens such as
capsular polysaccharides and other haemophilus influenza bacterial
antigen components; anthrax bacterial antigens such as anthrax
protective antigen and other anthrax bacterial antigen components;
rickettsiae bacterial antigens such as rompA and other rickettsiae
bacterial antigen component. Also included with the bacterial
antigens described herein are any other bacterial, mycobacterial,
mycoplasmal, rickettsial, or chlamydial antigens. Partial or whole
pathogens may also be: haemophilus influenza; Plasmodium
falciparum; neisseria meningitidis; streptococcus pneumoniae;
neisseria gonorrhoeae; salmonella serotype typhi; shigella; vibrio
cholerae; Dengue Fever; Encephalitides; Japanese Encephalitis; Lyme
disease; Yersinia pestis; west nile virus; yellow fever; tularemia;
hepatitis (viral; bacterial); RSV (respiratory syncytial virus);
HPIV 1 and HPIV 3; adenovirus; small pox; allergies and
cancers.
[0061] Fungal antigens for use with compositions and methods of the
invention include, but are not limited to, e.g., candida fungal
antigen components; histoplasma fungal antigens such as heat shock
protein 60 (HSP60) and other histoplasma fungal antigen components;
cryptococcal fungal antigens such as capsular polysaccharides and
other cryptococcal fungal antigen components; coccidiodes fungal
antigens such as spherule antigens and other coccidiodes fungal
antigen components; and tinea fungal antigens such as trichophytin
and other coccidiodes fungal antigen components.
[0062] Examples of protozoal and other parasitic antigens include,
but are not limited to, e.g., plasmodium falciparum antigens such
as merozoite surface antigens, sporozoite surface antigens,
circumsporozoite antigens, gametocyte/gamete surface antigens,
blood-stage antigen pf 155/RESA and other plasmodial antigen
components; toxoplasma antigens such as SAG-1, p30 and other
toxoplasmal antigen components; schistosomae antigens such as
glutathione-S-transferase, paramyosin, and other schistosomal
antigen components; leishmania major and other leishmaniae antigens
such as gp63, lipophosphoglycan and its associated protein and
other leishmanial antigen components; and trypanosoma cruzi
antigens such as the 75-77 kDa antigen, the 56 kDa antigen and
other trypanosomal antigen components.
[0063] Antigen that can be targeted using the rAb of the present
invention will generally be selected based on a number of factors,
including: likelihood of internalization, level of immune cell
specificity, type of immune cell targeted, level of immune cell
maturity and/or activation and the like. Examples of cell surface
markers for dendritic cells include, but are not limited to, MHC
class I, MHC Class II, B7-2, CD18, CD29, CD31, CD43, CD44, CD45,
CD54, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR and/or ASPGR and the
like; while in some cases also having the absence of CD2, CD3, CD4,
CD8, CD14, CD15, CD16, CD 19, CD20, CD56, and/or CD57. Examples of
cell surface markers for antigen presenting cells include, but are
not limited to, MHC class I, MHC Class II, CD40, CD45, B7-1, B7-2,
IFN-.gamma. receptor and IL-2 receptor, ICAM-1 and/or Fc.gamma.
receptor. Examples of cell surface markers for T cells include, but
are not limited to, CD3, CD4, CD8, CD 14, CD20, CD11b, CD16, CD45
and HLA-DR.
[0064] Target antigens on cell surfaces for delivery includes those
characteristic of tumor antigens typically will be derived from the
cell surface, cytoplasm, nucleus, organelles and the like of cells
of tumor tissue. Examples of tumor targets for the antibody portion
of the present invention include, without limitation, hematological
cancers such as leukemias and lymphomas, neurological tumors such
as astrocytomas or glioblastomas, melanoma, breast cancer, lung
cancer, head and neck cancer, gastrointestinal tumors such as
gastric or colon cancer, liver cancer, pancreatic cancer,
genitourinary tumors such cervix, uterus, ovarian cancer, vaginal
cancer, testicular cancer, prostate cancer or penile cancer, bone
tumors, vascular tumors, or cancers of the lip, nasopharynx,
pharynx and oral cavity, esophagus, rectum, gall bladder, biliary
tree, larynx, lung and bronchus, bladder, kidney, brain and other
parts of the nervous system, thyroid, Hodgkin's disease,
non-Hodgkin's lymphoma, multiple myeloma and leukemia.
[0065] Examples of antigens that may be delivered alone or in
combination to immune cells for antigen presentation using the
present invention include tumor proteins, e.g., mutated oncogenes;
viral proteins associated with tumors; and tumor mucins and
glycolipids. The antigens may be viral proteins associated with
tumors would be those from the classes of viruses noted above.
Certain antigens may be characteristic of tumors (one subset being
proteins not usually expressed by a tumor precursor cell), or may
be a protein which is normally expressed in a tumor precursor cell,
but having a mutation characteristic of a tumor. Other antigens
include mutant variant(s) of the normal protein having an altered
activity or subcellular distribution, e.g., mutations of genes
giving rise to tumor antigens.
[0066] Specific non-limiting examples of tumor antigens include:
CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE
1-4, 6 and 12, MUC (Mucin) (e.g., MUC-1, MUC-2, etc.), GM2 and GD2
gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), Pmel
17(gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase
V intron V sequence), Prostate Ca psm, PRAME (melanoma antigen),
.beta.-catenin, MUM-1-B (melanoma ubiquitous mutated gene product),
GAGE (melanoma antigen) 1, BAGE (melanoma antigen) 2-10, c-ERB2
(Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6, gp75,
human papilloma virus (HPV) E6 and E7, p53, lung resistance protein
(LRP), Bcl-2, and Ki-67. In addition, the immunogenic molecule can
be an autoantigen involved in the initiation and/or propagation of
an autoimmune disease, the pathology of which is largely due to the
activity of antibodies specific for a molecule expressed by the
relevant target organ, tissue, or cells, e.g., SLE or MG. In such
diseases, it can be desirable to direct an ongoing
antibody-mediated (i.e., a Th2-type) immune response to the
relevant autoantigen towards a cellular (i.e., a Th1-type) immune
response. Alternatively, it can be desirable to prevent onset of or
decrease the level of a Th2 response to the autoantigen in a
subject not having, but who is suspected of being susceptible to,
the relevant autoimmune disease by prophylactically inducing a Th1
response to the appropriate autoantigen. Autoantigens of interest
include, without limitation: (a) with respect to SLE, the Smith
protein, RNP ribonucleoprotein, and the SS-A and SS-B proteins; and
(b) with respect to MG, the acetylcholine receptor. Examples of
other miscellaneous antigens involved in one or more types of
autoimmune response include, e.g., endogenous hormones such as
luteinizing hormone, follicular stimulating hormone, testosterone,
growth hormone, prolactin, and other hormones.
[0067] Antigens involved in autoimmune diseases, allergy, and graft
rejection can be used in the compositions and methods of the
invention. For example, an antigen involved in any one or more of
the following autoimmune diseases or disorders can be used in the
present invention: diabetes, diabetes mellitus, arthritis
(including rheumatoid arthritis, juvenile rheumatoid arthritis,
osteoarthritis, psoriatic arthritis), multiple sclerosis,
myasthenia gravis, systemic lupus erythematosis, autoimmune
thyroiditis, dermatitis (including atopic dermatitis and eczematous
dermatitis), psoriasis, Sjogren's Syndrome, including
keratoconjunctivitis sicca secondary to Sjogren's Syndrome,
alopecia greata, allergic responses due to arthropod bite
reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis,
keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma,
cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis,
drug eruptions, leprosy reversal reactions, erythema nodosum
leprosum, autoimmune uveitis, allergic encephalomyelitis, acute
necrotizing hemorrhagic encephalopathy, idiopathic bilateral
progressive sensorineural hearing loss, aplastic anemia, pure red
cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's
granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome,
idiopathic sprue, lichen planus, Crohn's disease, Graves
ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis
posterior, and interstitial lung fibrosis. Examples of antigens
involved in autoimmune disease include glutamic acid decarboxylase
65 (GAD 65), native DNA, myelin basic protein, myelin proteolipid
protein, acetylcholine receptor components, thyroglobulin, and the
thyroid stimulating hormone (TSH) receptor. Examples of antigens
involved in allergy include pollen antigens such as Japanese cedar
pollen antigens, ragweed pollen antigens, rye grass pollen
antigens, animal derived antigens such as dust mite antigens and
feline antigens, histocompatiblity antigens, and penicillin and
other therapeutic drugs. Examples of antigens involved in graft
rejection include antigenic components of the graft to be
transplanted into the graft recipient such as heart, lung, liver,
pancreas, kidney, and neural graft components. The antigen may be
an altered peptide ligand useful in treating an autoimmune
disease.
[0068] As used herein, the term "epitope(s)" refer to a peptide or
protein antigen that includes a primary, secondary or tertiary
structure similar to an epitope located within any of a number of
pathogen polypeptides encoded by the pathogen DNA or RNA. The level
of similarity will generally be to such a degree that monoclonal or
polyclonal antibodies directed against such polypeptides will also
bind to, react with, or otherwise recognize, the peptide or protein
antigen. Various immunoassay methods may be employed in conjunction
with such antibodies, such as, for example, Western blotting,
ELISA, RIA, and the like, all of which are known to those of skill
in the art. The identification of pathogen epitopes, and/or their
functional equivalents, suitable for use in vaccines is part of the
present invention. Once isolated and identified, one may readily
obtain functional equivalents. For example, one may employ the
methods of Hopp, as taught in U.S. Pat. No. 4,554,101, incorporated
herein by reference, which teaches the identification and
preparation of epitopes from amino acid sequences on the basis of
hydrophilicity. The methods described in several other papers, and
software programs based thereon, can also be used to identify
epitopic core sequences (see, for example, Jameson and Wolf, 1988;
Wolf et al., 1988; U.S. Pat. No. 4,554,101). The amino acid
sequence of these "epitopic core sequences" may then be readily
incorporated into peptides, either through the application of
peptide synthesis or recombinant technology.
[0069] The preparation of vaccine compositions that includes the
nucleic acids that encode antigens of the invention as the active
ingredient, may be prepared as injectables, either as liquid
solutions or suspensions; solid forms suitable for solution in, or
suspension in, liquid prior to infection can also be prepared. The
preparation may be emulsified, encapsulated in liposomes. The
active immunogenic ingredients are often mixed with carriers which
are pharmaceutically acceptable and compatible with the active
ingredient.
[0070] The term "pharmaceutically acceptable carrier" refers to a
carrier that does not cause an allergic reaction or other untoward
effect in subjects to whom it is administered. Suitable
pharmaceutically acceptable carriers include, for example, one or
more of water, saline, phosphate buffered saline, dextrose,
glycerol, ethanol, or the like and combinations thereof. In
addition, if desired, the vaccine can contain minor amounts of
auxiliary substances such as wetting or emulsifying agents, pH
buffering agents, and/or adjuvants which enhance the effectiveness
of the vaccine. Examples of adjuvants that may be effective include
but are not limited to: aluminum hydroxide,
N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP),
N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, MTP-PE and RIBI,
which contains three components extracted from bacteria,
monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton
(MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. Other examples of
adjuvants include DDA (dimethyldioctadecylammonium bromide),
Freund's complete and incomplete adjuvants and QuilA. In addition,
immune modulating substances such as lymphokines (e.g.,
IFN-.gamma., IL-2 and IL-12) or synthetic IFN-.gamma. inducers such
as poly I:C can be used in combination with adjuvants described
herein.
[0071] Pharmaceutical products that may include a naked
polynucleotide with a single or multiple copies of the specific
nucleotide sequences that bind to specific DNA-binding sites of the
apolipoproteins present on plasma lipoproteins as described in the
current invention. The polynucleotide may encode a biologically
active peptide, antisense RNA, or ribozyme and will be provided in
a physiologically acceptable administrable form. Another
pharmaceutical product that may spring from the current invention
may include a highly purified plasma lipoprotein fraction, isolated
according to the methodology, described herein from either the
patient's blood or other source, and a polynucleotide containing
single or multiple copies of the specific nucleotide sequences that
bind to specific DNA-binding sites of the apolipoproteins present
on plasma lipoproteins, prebound to the purified lipoprotein
fraction in a physiologically acceptable, administrable form.
[0072] Yet another pharmaceutical product may include a highly
purified plasma lipoprotein fraction which contains recombinant
apolipoprotein fragments containing single or multiple copies of
specific DNA-binding motifs, prebound to a polynucleotide
containing single or multiple copies of the specific nucleotide
sequences, in a physiologically acceptable administrable form. Yet
another pharmaceutical product may include a highly purified plasma
lipoprotein fraction which contains recombinant apolipoprotein
fragments containing single or multiple copies of specific
DNA-binding motifs, prebound to a polynucleotide containing single
or multiple copies of the specific nucleotide sequences, in a
physiologically acceptable administrable form.
[0073] The dosage to be administered depends to a great extent on
the body weight and physical condition of the subject being treated
as well as the route of administration and frequency of treatment.
A pharmaceutical composition that includes the naked polynucleotide
prebound to a highly purified lipoprotein fraction may be
administered in amounts ranging from 1 .mu.g to 1 mg polynucleotide
and 1 .mu.g to 100 mg protein.
[0074] Administration of an rAb and rAb complexes a patient will
follow general protocols for the administration of
chemotherapeutics, taking into account the toxicity, if any, of the
vector. It is anticipated that the treatment cycles would be
repeated as necessary. It also is contemplated that various
standard therapies, as well as surgical intervention, may be
applied in combination with the described gene therapy.
[0075] Where clinical application of a gene therapy is
contemplated, it will be necessary to prepare the complex as a
pharmaceutical composition appropriate for the intended
application. Generally this will entail preparing a pharmaceutical
composition that is essentially free of pyrogens, as well as any
other impurities that could be harmful to humans or animals. One
also will generally desire to employ appropriate salts and buffers
to render the complex stable and allow for complex uptake by target
cells.
[0076] Aqueous compositions of the present invention may include an
effective amount of the compound, dissolved or dispersed in a
pharmaceutically acceptable carrier or aqueous medium. Such
compositions can also be referred to as inocula. The use of such
media and agents for pharmaceutical active substances is well known
in the art. Except insofar as any conventional media or agent is
incompatible with the active ingredient, its use in the therapeutic
compositions is contemplated. Supplementary active ingredients also
can be incorporated into the compositions. The compositions of the
present invention may include classic pharmaceutical preparations.
Dispersions also can be prepared in glycerol, liquid polyethylene
glycols, and mixtures thereof and in oils. Under ordinary
conditions of storage and use, these preparations contain a
preservative to prevent the growth of microorganisms.
[0077] Disease States. Depending on the particular disease to be
treated, administration of therapeutic compositions according to
the present invention will be via any common route so long as the
target tissue is available via that route in order to maximize the
delivery of antigen to a site for maximum (or in some cases
minimum) immune response. Administration will generally be by
orthotopic, intradermal, subcutaneous, intramuscular,
intraperitoneal or intravenous injection. Other areas for delivery
include: oral, nasal, buccal, rectal, vaginal or topical. Topical
administration would be particularly advantageous for treatment of
skin cancers. Such compositions would normally be administered as
pharmaceutically acceptable compositions that include
physiologically acceptable carriers, buffers or other
excipients.
[0078] Vaccine or treatment compositions of the invention may be
administered parenterally, by injection, for example, either
subcutaneously or intramuscularly. Additional formulations which
are suitable for other modes of administration include
suppositories, and in some cases, oral formulations or formulations
suitable for distribution as aerosols. In the case of the oral
formulations, the manipulation of T-cell subsets employing
adjuvants, antigen packaging, or the addition of individual
cytokines to various formulation that result in improved oral
vaccines with optimized immune responses. For suppositories,
traditional binders and carriers may include, for example,
polyalkylene glycols or triglycerides; such suppositories may be
formed from mixtures containing the active ingredient in the range
of 0.5% to 10%, preferably 1%-2%. Oral formulations include such
normally employed excipients as, for example, pharmaceutical grades
of mannitol, lactose, starch magnesium stearate, sodium saccharine,
cellulose, magnesium carbonate, and the like. These compositions
take the form of solutions, suspensions, tablets, pills, capsules,
sustained release formulations or powders and contain 10%-95% of
active ingredient, preferably 25-70%.
[0079] The antigen encoding nucleic acids of the invention may be
formulated into the vaccine or treatment compositions as neutral or
salt forms. Pharmaceutically acceptable salts include the acid
addition salts (formed with free amino groups of the peptide) and
which are formed with inorganic acids such as, for example,
hydrochloric or phosphoric acids, or with organic acids such as
acetic, oxalic, tartaric, maleic, and the like. Salts formed with
the free carboxyl groups can also be derived from inorganic bases
such as, for example, sodium, potassium, ammonium, calcium, or
ferric hydroides, and such organic bases as isopropylamine,
trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the
like.
[0080] Vaccine or treatment compositions are administered in a
manner compatible with the dosage formulation, and in such amount
as will be prophylactically and/or therapeutically effective. The
quantity to be administered depends on the subject to be treated,
including, e.g., capacity of the subject's immune system to
synthesize antibodies, and the degree of protection or treatment
desired. Suitable dosage ranges are of the order of several hundred
micrograms active ingredient per vaccination with a range from
about 0.1 mg to 1000 mg, such as in the range from about 1 mg to
300 mg, and preferably in the range from about 10 mg to 50 mg.
Suitable regiments for initial administration and booster shots are
also variable but are typified by an initial administration
followed by subsequent inoculations or other administrations.
Precise amounts of active ingredient required to be administered
depend on the judgment of the practitioner and may be peculiar to
each subject. It will be apparent to those of skill in the art that
the therapeutically effective amount of nucleic acid molecule or
fusion polypeptides of this invention will depend, inter alia, upon
the administration schedule, the unit dose of antigen administered,
whether the nucleic acid molecule or fusion polypeptide is
administered in combination with other therapeutic agents, the
immune status and health of the recipient, and the therapeutic
activity of the particular nucleic acid molecule or fusion
polypeptide.
[0081] The compositions can be given in a single dose schedule or
in a multiple dose schedule. A multiple dose schedule is one in
which a primary course of vaccination may include, e.g., 1-10
separate doses, followed by other doses given at subsequent time
intervals required to maintain and or reinforce the immune
response, for example, at 1-4 months for a second dose, and if
needed, a subsequent dose(s) after several months. Periodic
boosters at intervals of 1-5 years, usually 3 years, are desirable
to maintain the desired levels of protective immunity. The course
of the immunization can be followed by in vitro proliferation
assays of peripheral blood lymphocytes (PBLs) co-cultured with
ESAT6 or ST-CF, and by measuring the levels of IFN-.gamma. released
from the primed lymphocytes. The assays may be performed using
conventional labels, such as radionucleotides, enzymes, fluorescent
labels and the like. These techniques are known to one skilled in
the art and can be found in U.S. Pat. Nos. 3,791,932, 4,174,384 and
3,949,064, relevant portions incorporated by reference.
[0082] The modular rAb carrier and/or conjugated rAb
carrier-(cohesion/dockerin and/or dockerin-cohesin)-antigen complex
(rAb-DC/DC-antigen vaccine) may be provided in one or more "unit
doses" depending on whether the nucleic acid vectors are used, the
final purified proteins, or the final vaccine form is used. Unit
dose is defined as containing a predetermined-quantity of the
therapeutic composition calculated to produce the desired responses
in association with its administration, i.e., the appropriate route
and treatment regimen. The quantity to be administered, and the
particular route and formulation, are within the skill of those in
the clinical arts. The subject to be treated may also be evaluated,
in particular, the state of the subject's immune system and the
protection desired. A unit dose need not be administered as a
single injection but may include continuous infusion over a set
period of time. Unit dose of the present invention may conveniently
may be described in terms of DNA/kg (or protein/Kg) body weight,
with ranges between about 0.05, 0.10, 0.15, 0.20, 0.25, 0.5, 1, 10,
50, 100, 1,000 or more mg/DNA or protein/kg body weight are
administered. Likewise the amount of rAb-DC/DC-antigen vaccine
delivered can vary from about 0.2 to about 8.0 mg/kg body weight.
Thus, in particular embodiments, 0.4 mg, 0.5 mg, 0.8 mg, 1.0 mg,
1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 4.0 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5
mg, 7.0 mg and 7.5 mg of the vaccine may be delivered to an
individual in vivo. The dosage of rAb-DC/DC-antigen vaccine to be
administered depends to a great extent on the weight and physical
condition of the subject being treated as well as the route of
administration and the frequency of treatment. A pharmaceutical
composition that includes a naked polynucleotide prebound to a
liposomal or viral delivery vector may be administered in amounts
ranging from 1 .mu.g to 1 mg polynucleotide to 1 .mu.g to 100 mg
protein. Thus, particular compositions may include between about 1
.mu.g, 5 .mu.g, 10 .mu.g, 20 .mu.g, 30 .mu.g, 40 .mu.g, 50 .mu.g,
60 .mu.g, 70 .mu.g, 80 .mu.g, 100 .mu.g, 150 .mu.g, 200 .mu.g, 250
.mu.g, 500 .mu.g, 600 .mu.g, 700 .mu.g, 800 .mu.g, 900 .mu.g or
1,000 .mu.g polynucleotide or protein that is bound independently
to 1 .mu.g, 5 .mu.g, 10 .mu.g, 20 .mu.g, 3.0 .mu.g, 40 .mu.g 50
.mu.g, 60 .mu.g, 70 .mu.g, 80 .mu.g, 100 .mu.g, 150 .mu.g, 200
.mu.g, 250 .mu.g, 500 .mu.g, 600 .mu.g, 700 .mu.g, 800 .mu.g, 900
.mu.g, 1 mg, 1.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60
mg, 70 mg, 80 mg, 90 mg or 100 mg vector.
[0083] The present invention was tested in an in vitro cellular
system that measures immune stimulation of human Flu-specific T
cells by dendritic cells to which Flu antigen has been targeted.
The results shown herein demonstrate the specific expansion of such
antigen specific cells at doses of the antigen which are by
themselves ineffective in this system.
[0084] The present invention may also be used to make a modular rAb
carrier that is, e.g., a recombinant humanized mAb (directed to a
specific human dendritic cell receptor) complexed with protective
antigens from Ricin, Anthrax toxin, and Staphylococcus B
enterotoxin. The potential market for this entity is vaccination of
all military personnel and stored vaccine held in reserve to
administer to large population centers in response to any biothreat
related to these agents. The invention has broad application to the
design of vaccines in general, both for human and animal use.
Industries of interest include the pharmaceutical and biotechnology
industries.
[0085] General methods--Restriction and DNA modification enzymes
were from NEB. Plasmid and DNA fragment purification was with
Qiagen products. SDS-PAGE was via 4-12% Bis-Tris gels stained with
Simply Blue (Invitrogen). Chromatography columns and resins were
from GE Healthcare. Plasmid constructs were confirmed by DNA
sequencing (MCLAB). DNA primers were from Operon or Midland
Certified Reagent Company. Sequence analysis was via Sequencher
(Gene Codes). Protein concentrations based on calculated extinction
coefficient predicted by the ProtParam tool (2005) were measured by
UV absorption (NanoDrop ND-1000). The sequences are provided in the
Sequence Listing SEQ ID NOS.: 1-39, incorp[orated herein by
reference, which are alignments anti-DCIR mAb Heavy (SEQ ID NOS.:
1-17) and Light chain signal peptide and variable region sequences
(SEQ ID NOS.:18-39). Predicted N-terminal signal peptide region,
sequence differences between variants or between closely related
sequences were determined using Sequencher.
[0086] Sequence of the C-terminal extension to the Cohesin domain
of Cohesin-Flex-hMART-1-PeptideA-6.times.His protein. The
immunodominant peptide sequence peptide is underlined and bold
residues bounding the peptide are native to the antigen sequence.
C-terminal His tags are to facilitate purification via Ni++
affinity chromatography. C186 Cohesin-Flex-hMART-1-Peptide
A-6.times.His:
TABLE-US-00001 (SEQ ID NO.: 40)
ASDTTEARHPPVTTPTTDRRKGTTAEELAGIGILTVILGGKRTNNSTPTKGEFCRYPSHW
RPLEHHHHHH.
[0087] Antigen expression constructs--PCR was used to amplify the
ORF of Influenza A/Puerto Rico/8/34/Mount Sinai (H1N1) M1 protein
while incorporating a Nhe I site distal to the initiator codon and
a Not I site distal to the stop codon. The digested fragment was
cloned into pET-28b(+) (Novagen), placing the M1 ORF in-frame with
a His6 tag, thus encoding His.Flu M1 protein. The Flu M1 ORF was
placed into a similar vector encoding N-terminal protein G
precursor B2 domain residues 298-352 (gi|124267|) distal to the Nco
I site, followed by linker residues encoding GGSGGSGGSLD (SEQ ID
NO.: 41). This vector expressed ProG.Flu M1 protein with a Q246E
change. A pET28b (+) derivative encoding a N-terminal 169 residue
cohesin domain from C. thermocellum inserted between the Nco I and
Nhe I sites expressed Coh.His. For expression of Coh.Flu M1.His,
the Flu M1 ORF was inserted between the Nhe I and Xho I sites of
the above derivative. Coh.PEP.His expression constructs were made
similarly, except they utilized synthetic DNAs encoding the
required sequences. The proteins were expressed in E. coli strain
BL21 (DE3) (Novagen) or T7 Express (NEB) grown at 37.degree. C.
with selection for kanamycin resistance (40 .mu.g/ml) and shaking
at 200 rounds/min to mid log phase growth when 120 mg/L IPTG was
added. After three hours, the cells were harvested by
centrifugation and stored at -80 C. The ProG and Cohesin segments
replaced the ectodomain segment in the AP fusion secretion vector
described above, by incorporating a Sal I site in place of the
initiator codon and adding a distal Xho I site for insertion at the
vector Xho I site. An `empty` AP vector was made by deleting the
ectodomain segment. Respectively, these constructs directed
secreted of ProG.AP, Coh.AP and AP.
[0088] Expression and purification of recombinant proteins--E. coli
cells from each 1 L fermentation were resuspended in 30 ml ice-cold
0.1 M NaPO.sub.4 pH 7.4 (buffer A, for ProG.Flu M1) or 50 mM Tris,
1 mM EDTA pH 8.0 (buffer B, for all other proteins) with 0.1 ml of
protease inhibitor Cocktail II (Calbiochem). The cells were
sonicated on ice 2.times.5 min at setting 18 (Fisher Sonic
Dismembrator 60) with a 5 min rest period and then spun at 17,000
r.p.m. (Sorvall SA-600) for 20 min at 4.degree. C. For ProG.Flu M1,
the supernatant was passed through 5 ml Q Sepharose equilibrated in
buffer A and then 5 ml hIgG beads were added to the Q flow-through
and incubated with mixing at 4.degree. C. for 1 h. The bead-bound
protein was washed with 50 ml cold PBS and eluted with 2.times.10
ml 0.1 M glycine pH 2.7. The pooled eluates were brought to pH 5
with 0.1 M MES pH 5.0 buffer and run on a 1 ml HiTrap S column
equilibrated with 50 mM MES pH 5.0 (buffer C). The column-bound
protein was washed extensively with buffer C and eluted with a 0-1
M NaCl gradient in buffer C. The peak fractions were pooled. For
His.Flu M1 purification the 50 ml cell lysate supernatant fraction
was passed through 5 ml Q Sepharose beads and 6.25 ml 160 mM Tris,
40 mM imidazole, 4 M NaCl pH 7.9 was added to the Q Sepharose flow
through. This was loaded at 4 ml/min onto a 5 ml HiTrap chelating
HP column charged with Ni.sup.++. The column-bound protein was
washed with 20 mM NaPO.sub.4, 300 mM NaCl pH 7.6 (buffer D)
followed by another wash with 100 mM H.sub.3COONa pH 4.0. Bound
protein was eluted with a gradient from 100 mM to 1 M H.sub.3COONa
pH 4.0. The peak fractions were pooled and loaded at 4 ml/min onto
a 5 ml HiTrap S column equilibrated with 100 mM H.sub.3COONa pH
4.0, and washed with the equilibration buffer followed by another
wash with 50 mM NaPO.sub.4 pH 7.5. Bound protein was eluted with a
gradient from 0-1 M NaCl in 50 mM NaPO.sub.4 pH 7.5. Peak fractions
eluting at about 500 mM NaCl were pooled. Preparations of His.Flu
M1 had variable amounts of non-full-length products, presumably
with C-terminal portions missing. For Coh.Flu M1.His purification,
cells from 2 L of culture were sonicated as above, but in buffer B.
After centrifugation, 2.5 ml of Triton X114 was added to the
supernatant with incubation on ice for 5 min. After further
incubation at 25.degree. C. for 5 min, the supernatant was
separated from the Triton X114 following centrifugation at
25.degree. C. The extraction was repeated and the supernatant was
passed through 5 ml of Q Sepharose beads and 6.25 ml 160 mM Tris,
40 mM imidazole, 4 M NaCl pH 7.9 was added to the Q Sepharose flow
through. The protein was then purified by Ni.sup.++ chelating
chromatography as described above and eluted with 0-500 mM
imidazole in buffer D.
[0089] cDNA cloning and expression of chimeric mouse/human
mAbs--Total RNA was prepared from hybridoma cells (RNeasy kit,
Qiagen) and used for cDNA synthesis and PCR (SMART RACE kit, BD
Biosciences) using supplied 5' primers and gene specific 3' primers
mIgG.kappa., 5' ggatggtgggaagatggatacagttggtgcagcatc3'; (SEQ ID
NO.: 42) mIgG.lamda., 5'
ctaggaacagtcagcacgggacaaactcttctccacagtgtgaccttc3'; (SEQ ID NO.:
43) mIgG1, 5' gtcactggctcagggaaatagcccttgaccaggcatc3'; (SEQ ID NO.:
44) mIgG2a, 5' ccaggcatectagagtcaccgaggagccagt3'; (SEQ ID NO.: 45)
and mIgG2b, 5' ggtgctggaggggacagtcactgagctgctcatagtgt3'. (SEQ ID
NO.: 46) PCR products were cloned (pCR2.1 TA kit, Invitrogen) and
characterized by DNA sequencing. Using the derived sequences for
the mouse H and L chain V-region cDNAs, specific primers were used
to PCR amplify the signal peptide and V-regions while incorporating
flanking restriction sites for cloning into expression vectors
encoding downstream human IgG.kappa. or IgG4H regions. The vector
for expression of chimeric mV.kappa.-hIg.kappa. was built by
amplifying residues 401-731 (gi|63101937|) flanked by Xho I and Not
I sites and inserting this into the Xho I-Not I interval of
pIRES2-DsRed2 (BD Biosciences). PCR was used to amplify the mAb Vk
region from the initiator codon, appending a Nhe I or Spe I site
then CACC, to the region encoding (e.g., residue 126 of
gi|76779294|), appending a Xho I site. The PCR fragment was then
cloned into the Nhe I-Not I interval of the above vector. The
vector for chimeric mV.kappa.-hIg.kappa. using the mSLAM leader was
built by inserting the sequence 5'
ctagttgctggctaatggaccccaaaggctccctttcctggagaatacttctgtttctctccctggcttttga-
gttgtcgtacggattaattaag ggcccactcgag3' (SEQ ID NO.: 47) into the Nhe
I-Xho I interval of the above vector. PCR was used to amplify the
interval between the predicted mature N-terminal codon (defined
using the SignalP 3.0 Server) (Bendtsen, Nielsen et al. 2004) and
the end of the mV.kappa. region (as defined above) while appending
5' tcgtacgga3'. The fragment digested with Bsi WI and Xho I was
inserted into the corresponding sites of the above vector. The
control hIg.kappa. sequence corresponds to gi|49257887| residues
26-85 and gi|21669402| residues 67-709. The control hIgG4H vector
corresponds to residues 12-1473 of gi|19684072| with S229P and
L236E substitutions, which stabilize a disulphide bond and abrogate
residual FcR binding (Reddy, Kinney et al. 2000), inserted between
the pIRES2-DsRed2 vector Bgl II and Not I sites while adding the
sequence 5' gctagctgattaattaa3' instead of the stop codon. PCR was
used to amplify the mAb VH region from the initiator codon,
appending CACC then a Bgl II site, to the region encoding residue
473 of gi|19684072|. The PCR fragment was then cloned into the Bgl
II-Apa I interval of the above vector. The vector for chimeric
mVH-hIgG4 sequence using the mSLAM leader was built by inserting
the sequence 5'
ctagttgctggctaatggaccccaaaggctccattcctggagaatacttctgtactctccctggctatgagag-
tcgtacggattaattaag ggccc3' (SEQ ID NO.: 48) into the Nhe I-Apa I
interval of the above vector. PCR was used to amplify the interval
between the predicted mature N-terminal codon and the end of the
mV.kappa. region while appending 5' tcgtacgga3'. The fragment
digested with Bsi WI and Apa I was inserted into the corresponding
sites of the above vector.
[0090] Various antigen coding sequences flanked by a proximal Nhe I
site and a distal Not I site following the stop codon were inserted
into the Nhe I-Pac I-Not I interval of the H chain vectors. Flu
HAl-1 was encoded by Influenza A virus (A/Puerto Rico/8/34(H1N1))
hemagglutinin gi|21693168| residues 82-1025 (with a C982T change)
with proximal 5' gctagcgatacaacagaacctgcaacacctacaacacctgtaacaa3'
(SEQ ID NO.: 49) sequence (a Nhe I site followed by sequence
encoding cipA cohesin-cohesin linker residues) and distal 5'
caccatcaccatcaccattgagcggccgc3' (SEQ ID NO.: 50) sequence (encoding
His6, a stop codon, and a Not I site). Flu HA5-1 was encoded by
gi|50296052| Influenza A virus (A/Viet Nam/1203/2004(H5N1))
hemagglutinin residues 49-990 bound by the same sequences as Flu
HAl-1. Doc was encoded by gi|40671| celD residues 1923-2150 with
proximal Nhe I and distal Not I sites. PSA was encoded by
gi|34784812| prostate specific antigen residues 101-832 with
proximal sequence 5'
gctagcgatacaacagaacctgcaacacctacaacacctgtaacaacaccgacaacaacacttctagcgc3'
(SEQ ID NO.: 51) (Nhe I site and cipA spacer) and a distal Not I
site. Flu M1-PEP was encoded by 5'
gctagccccattctgagccccctgaccaaaggcattctgggctttgtgtttaccctgaccgtgcccagcgaac-
gcaagggtatacttggat tcgttttcacacttacttaagcggccgc3'(SEQ ID NO.: 52).
This and all other peptide-encoding sequences were created via
mixtures of complimentary synthetic DNA fragments with ends
compatible for cloning into Nhe I and Not I-restricted H chain
vectors, or Nhe I-Xho I-restricted Coh.His vector. Preferred human
codons were always used, except where restriction sites needed to
be incorporated or in CipA spacer sequences.
[0091] Production levels of rAb expression constructs were tested
in 5 ml transient transfections using .about.2.5 .mu.g each of the
L-chain and H chain construct and the protocol described above.
Supernatants were analyzed by anti-hIgG ELISA (AffiniPure Goat
anti-human IgG (H+L), Jackson ImmunoResearch). In tests of this
protocol, production of secreted rAb was independent of H chain and
L chain vectors concentration over a .about.2-fold range of each
DNA concentration (i.e., the system was DNA saturated).
[0092] Generation of CD34-DCs-CD34+ HPCs were mobilized and
collected from peripheral blood of normal healthy donors, who
received subcutaneous recombinant G-CSF (Neupogen) 10 U/kg/day for
5 days. CD34.sup.+-HPCs were obtained with the CEPRATE SC stem cell
concentration system (ISOLEX). CD34-DCs were generated by culture
at a concentration of 0.5.times.10.sup.6/ml in Yssel's medium
(Irvine Scientific, CA) supplemented with 5% autologous serum, 50
.mu.M 2-.beta.-mercaptoethanol, 1% L-glutamine, 1%
penicillin/streptomycin, and the cytokines; GM-CSF (50 ng/ml;
Immunex Corp.), FLT3-L (100 ng/ml; R&D), and TNF-.alpha. (10
ng/ml; R&D). Cells were transferred to fresh medium
supplemented with cytokines at day 5 of culture, and harvested at
day 9.
[0093] Sorting of CD34-DCs-CD34-derived DCs at day 9 of culture
were harvested, and stained with anti-CD1a FITC (Biosource
International) and anti-CD14 PE (BD Biosciences).
CD1a.sup.+CD14.sup.--LCs and CD1a.sup.-CD14.sup.+-intDCs were
sorted with FACS Vantage.TM. (BD Biosciences). Purity was routinely
95-99%.
[0094] Purification of autologous CD8.sup.+ T cells--Autologous
CD8+ T cells were positively selected from PBMCs obtained from the
identical donors by using CD8 magnetic beads (Miltenyi) after
depletion with CD14, CD19, CD16, CD56 and CD4 beads. In some
experiments, memory CD8+ T cells were sorted as
CD8+CCR7-CD45RA-.
[0095] Cross-presentation of Flu M1 protein by CD34-DC subsets to
CD8.sup.+ T cells--Bulk or sorted CD34+DCs subsets, CD1a+LCs or
CD14+ IntDCs (5.times.10.sup.4 cells/ml) from an HLA-A2 donor, were
cultured with purified autologous CD8+ T cells (1.times.10.sup.6
cells/ml) in Yssel's medium supplemented with 10% heat-inactivated
pooled AB human serum, 10 U/ml IL-7 (R&D) and decreasing doses
of Flu M1 that was cross-linked to an anti-DC antibody. CD40L was
added to the culture after 24 h, and IL-2 was added after 3 days.
Cross presentation efficiency was assessed after 8 or 10 days, by
analyzing the level of antigen-specific CD8+ T cell proliferation,
using specific Flu M1, HLA-A201/pMI, phycoerythrin-conjugated iTAg
MHC Tetramer (Beckman Coulter).
[0096] Development of anti-human DCIR monoclonal
antibodies--Receptor ectodomain.hIgG (human IgG1Fc) and HRP (horse
radish peroxidase) fusion proteins were produced for immunization
of mice and screening of mAbs, respectively. The expression
construct for hDCIR ectodomain.IgG was described previously (Bates,
Fournier et al. 1999) and used the mouse SLAM (mSLAM) signal
peptide to direct secretion (Bendtsen, Nielsen et al. 2004). The
expression vector for hDCIR ectodomain.AP was generated using PCR
to amplify AP resides 133-1581 (gb|BC009647|) while adding a
proximal in-frame Xho I site and a distal TGA stop codon and Not I
site. This Xho I-Not I fragment replaced the IgG coding sequence in
the above hDCIR ectodomain.IgG vector. The DCIR.HRP fusion protein
vector was generated by cloning gi|208493| residues 14-940 distal
to the DCIR ectodomain-coding region as defined above.
[0097] Expression and purification of recombinant proteins secreted
from mammalian cells--Fusion proteins were produced using the
FreeStyle.TM. 293 Expression System (Invitrogen) according to the
manufacturer's protocol (1 mg total plasmid DNA with 1.3 ml 293
Fectin reagent/L of transfection). For recombinant antibody (rAb)
production, equal amounts of vector encoding the H and L chain were
co-transfected. Transfected cells are cultured for 3 days, the
culture supernatant was harvested and fresh media added with
continued incubation for two days. The pooled supernatants were
clarified by filtration. Receptor ectodomain.hIgG was purified by
HiTrap protein A affinity chromatography with elution by 0.1 M
glycine pH 2.7 and then dialyzed versus PBS. rAbs were purified
similarly, by using HiTrap MabSelect.TM. columns.
[0098] Generation of monoclonal antibodies--Mouse mAbs were
generated by conventional cell fusion technology. Briefly,
6-week-old BALB/c mice were immunized intraperitoneally with 20
.mu.g of receptor ectodomain.hIgGFc fusion protein with Ribi
adjuvant, then boosts with 20 .mu.g antigen 10 days and 15 days
later. After 3 months, the mice were boosted again three days prior
to taking the spleens. Alternately, mice were injected in the
footpad with 1-10 .mu.g antigen in Ribi adjuvant every 3-4 days
over a 30-40 day period. 3-4 days after a final boost, draining
lymph nodes were harvested. B cells from spleen or lymph node cells
were fused with SP2/O--Ag 14 cells (Shulman, Wilde et al. 1978)
using conventional techniques. ELISA was used to screen hybridoma
supernatants against the receptor ectodomain fusion protein
compared to the fusion partner alone, or versus the receptor
ectodomain fused to AP (Bates, Fournier et al. 1999). Positive
wells were then screened in FACS using 293F cells transiently
transfected with expression plasmids encoding full-length receptor
cDNAs.
[0099] For the development of anti-DCIR mAbs, supernatants from
1000 hybridoma clones screened: [0100] 90 were + on DCIR.Ig vs. Ig
ELISA [0101] 64 were + on DCIR-293 cells by FACS [0102] 62 FACS+
were ELISA+ [0103] 2 were 293+ (and thus not specific to DCIR)
[0104] Biological screen for anti-DCIR mAbs that stimulate cytokine
production by human DC--For DC-targeting purposes, it is
potentially desirable to have the antibody delivering the antigen
to the DC and concomitantly activating the DC to stimulate a
productive immune response against the delivered antigen. Thus we
screened the panel of 62 FACS positive anti-DCIR hybridoma
supernatants directly for DC stimulation activity. CD34+-derived
human DC were cultured for 24 hours with the hybridoma supernatants
and the DC culture supernatant was assayed 24 hours later for the
presence of the chemokine MCP-1. The figure below shows that many,
but not all, hybridoma supernatants elicited specific production of
MCP-1 when compared to controls.
[0105] Selected hybridomas (most, but all stimulating MCP-1
production) marked in the figure above with asterisks were single
cell cloned and expanded in CELLine flasks (Intergra). Hybridoma
supernatants were mixed with an equal volume of 1.5 M glycine, 3 M
NaCl, 1.times.PBS, pH 7.8 and tumbled with MabSelect resin. The
resin was washed with binding buffer and eluted with 0.1 M glycine,
pH 2.7. Following neutralization with 2 M Tris, mAbs were dialyzed
versus PBS.
[0106] FIG. 1 shows that many, but not all, hybridoma supernatants
elicited specific production of MCP-1 when compared to controls,
namely mAbs 4C7, 9E8, 19E3, 1G3, 10A5, 29G10, 3C2, 3G2, 24A5, 30F3,
12E2, 5F9, 2F11, 24E7,31A6, 6A11,2 9E9, 2H8, 30D9, 6C8, 35F1, 3F12
were selected for further characterization.
[0107] Characterization of the pure anti-DCIR mAbs--The pure mAbs
were tested firstly by ELISA (DCIR.Ig bound to the plates,
developed with HRP-conjugated anti-human Fc reagents) and by a
DCIR.HRP capture assay (mAb bound to the plate, developed with
DCIR.HRP fusion protein). FIG. 2 shows representative assay results
showing high affinity interaction of the mAbs with DCIR bound to
plate (controls showing specificity of binding are not shown). In
the DCIR.HRP capture assay, several (but not all) of the mAbs were
able to capture soluble DCIR.HRP to the plate surface. These data
show that the panel of selected anti-DCIR mAbs had a range of DCIR
binding affinities and properties.
[0108] The pure mAbs were also tested for FACS reactivity, firstly
against 293 cells transiently transfected with expression plasmid
encoding full-length DCIR, and then against various types of
cultured and ex-vivo human DC. The figure below shows a
representative set of mAbs titrated in a FACS analysis versus DCIR
293 cell (control cells were negative).
[0109] FIG. 3 shows that CD34-derived human DC of both CD14+ and
CD1a+ subtypes express cell surface DCIR. These two DC subtypes
have profoundly different roles in directing humoral versus
cytolytic immune responses--thus the presence of DCIR on both
subtypes suggests that antigen targeted to human DC via DCIR should
elicit both types of immunity--an important feature of vaccines
directed against, e.g., viral infections.
[0110] FIG. 4 shows that DCIR is also expressed on three human DC
subtypes isolated directly from human skin. This observation shows
that for DCIR antigen targeting vaccines, administration into the
skin should be advantageous since these DC types all express the
receptor. It is known that these DC types are analogous to the
above cultured human DC regards their immune directing properties
and therefore targeting antigen through DCIR-bearing skin DC should
be advantageous for eliciting desirable mixed immune responses.
[0111] Dermal DCs and LCs were purified from normal human skin
specimens. Specimens were incubated in the bacterial protease
dispase type 2 for 18 h at 4.degree. C., and then for 2 h at
37.degree. C. Epidermal and dermal sheets were then separated, cut
into small pieces (.about.1-10 mm) and placed in RPMI 1640
supplemented with 10% fetal bovine serum (FBS). After 2 days, the
cells that migrated into the medium were collected and further
enriched using a Ficoll-diatrizoate gradient, 1.077 g/dl. DCs were
purified by cell sorting after staining with anti-CD1a FITC and
anti-CD14 APC mAbs.
[0112] Presence of DCIR in other human tissues. FIG. 5 shows
DCIR-specific staining of a population of cells surrounding a
germinal center within a human tonsil. These cells are likely to be
either resident DC or DC recently migrated to this site after e.g.,
loading with foreign antigen and activation. The staining shows
that administration of DCIR-targeted vaccines by routes other than
skin permitting access to organs in which immunity is generated
should also be advantageous for eliciting immune response.
[0113] Using anti-DCIR mAbs to target antigen to human DC. Flu M1
proteins were chemically cross-linked to mAbs using
sulfosuccinimidyl 6-[3' (2-pyridyldithio)-propionamido]hexanoate
(sulfo-LC-SPDP; Pierce) according to the manufacturer's protocol.
The multi-step protocol involved the activation of the mAb by
modification of its amines through the NHS ester group of SPDP for
30 min at room temperature followed by dialysis versus PBS.
Subsequently, Flu M1 proteins, which contain two free sulfhydryl
groups, were added and incubated at room temperature overnight. The
efficiency of the cross-linking reaction was estimated by comparing
the amount of Flu M1 protein before the reaction to the mAb, to the
mAb/Flu M1 ratio after cross-linking. We calculated that, on
average, 50% of the mAbs had reacted to one Flu M1 molecule. FIGS.
6 and 7 show examples of the cross-Flu M1 protein and the mAb to
DCIR. Analysis via reduced SDS-PAGE identified products with 1-2
Flu M1 per mAb based on the ratio of staining of Flu M1/H chain and
these preparations were used in the in vitro studies. Non-reduced
SDS-PAGE analysis (second figure below shows that the complexes
were largely between Flu M1 and single mAbs as evidenced by a low
percentage of very large complexes.
[0114] FIG. 6 shows the cross-linking of Coh.Flu M1 to
Anti-DCIR.sub.--2C9 mAb. Reduced SDS-PAGE analysis of cross-linked
products purified by protein G Sepharose affinity. From left to
right are 2.5 .mu.g, 1 .mu.g Coh.Flu M 1, 10 .mu.g products from
reacting Coh.Flu M1 with mAb at ratios of 1:1, 2:1, 4:1.
[0115] FIG. 7 shows the cross-linking of His.Flu M1 to mAbs.
Non-reduced SDS-PAGE analysis of cross-linked products purified by
protein G Sepharose affinity. From left to right are 5 .mu.g,
His.Flu M1, followed by pairs of 5 .mu.g mAb (anti-CD1a OKT6,
anti-LANG.sub.--2G3, anti-DCIR.sub.--2C9) and 5 .mu.g mAb reacted
with of 5 .mu.g His.Flu M1.
[0116] Anti-DC receptor mAbs cross-linked to Flu M1 protein
effectively target the antigen to human DC--Anti-DC receptor mAbs
were chemically cross-linked to Flu M1 protein and various doses
were added to the co-culture of human CD34-derived CD1a+DCs with
autologous CD8+ T cells. CD40L was added to the culture after 24 h
for DCs activation, followed by addition of IL-2, at day 3, for T
cell proliferation. After 8-10 days, T cells specific for the Flu
M1 peptide GILGFVFTL (SEQ ID NO.: 53) were assessed by MHC tetramer
analysis. FIG. 8 shows that Flu M1 cross-linked to anti-DCIR mAb
elicited the proliferation of Flu M1-specific cells, while
significantly less proliferation of Flu M1-specific cells was
observed with non-cross-linked Flu M1 and mAb at similar doses. The
dose-ranging shows that the cross-linked mAb elicited a response at
least 50-fold more effectively than free Flu M1. This data
demonstrates antigen-targeting, i.e., potentiation of an immune
response--in this case a recall of T cells with memory of a
specific Flu M1 epitope. CD34-DCs were sorted into CD1a+LCs or
CD14+IntDCs subsets. FIG. 9 shows that anti-DCIR-targeted CD1a+LCs
were much more potent at directing the expansion of Flu M1-specific
CD8+ cells, despite similar levels of DCIR expression on both cell
types.
[0117] FIG. 8 shows that Flu M1 cross-linked to anti-DCIR mAb
induces the expansion of Flu M1-specific CD8+ T cells more
efficiently than Flu M1 protein unlinked to mAb. CD34- derived
CD1a+ DCs were incubated with CD8+ T cells and the indicated
concentrations of anti-DCIR.sub.--2C9 mAb cross-linked to His.Flu
M1 or with unlinked mAb. CD8+ T cells were then analyzed for Flu
M1-specific expansion. The inner boxes indicate the percentages of
tetramer-specific CD8+ T cells.
[0118] FIG. 9 shows that Flu M1 cross-linked to anti-DCIR mAb
induces the expansion of Flu M1-specific CD8+ T cells more
efficiently via LCs than Int-DCs. LCs or Int-DCs from an HLA-A2
donor and autologous CD8+ T cells were co-cultured with the
indicated concentrations of anti-DCIR.sub.--2C9 mAb cross-linked to
His.Flu M1. Cross-presentation efficiency was assessed by the
frequency of Flu M1-specific CD8+ T cells and analyzed with
HLA-A201/pMI tetramer. The inner boxes indicate the percentages of
tetramer-specific CD8+ T cells.
[0119] Development of recombinant anti-DCIR mAbs (rAbs) as
prototype antigen-targeting vaccines. Vectors were developed for
the expression in transiently transfected mammalian cells of
secreted anti-DC receptor rAbs that were chimeras of the mouse
hybridoma-encoded H and L chain variable (V) regions and human
Ig.kappa. or human IgG4H constant (C) regions. V regions from L and
H chains of anti-DC receptor mAbs with different specificities
(I.e., from different anti-DCIR hybridomas) were cDNA cloned,
characterized by DNA sequence analysis, and engineered into these
vectors. FIG. 10 shows such H+L chain vectors encoding chimeric
mouse-human rAbs corresponding to a number of different anti-DCIR
mAbs co-transfected into 293 cells and assayed by anti-human FC
ELISA for secretion of rAb into the culture supernatant.
[0120] The anti-DCIR rAbs encoded a .about.9.5 kDA dockerin domain
in-frame with the rAb H chain. The purpose of the dockerin domain
(called rAb.Doc) is to permit assembly of specific
[rAb.Doc:Coh.antigen] complexes. In this case, Coh.antigen refers
to a fusion protein between a .about.17.5 kDa cohesin domain and an
antigen. High affinity interaction between cohesin and dockerin is
used to assemble defined complexes that we have shown deliver
antigen to the surface of DC bearing the receptor specificity. For
example, the figure below shows [anti-DCIR.Doc:Coh.Flu M1]
complexes bound to the surface of human DC (here the Coh.Flu M1 is
biotinylated and detected on the cell surface after washing steps).
Control rAb.Doc:Coh.Flu M1 complexes (shown in red in the figure
below) did not bind any more than the detecting streptavidin-PE
reagent alone.
[0121] DCIR internalizes antigen with slow kinetics and this
distinguishes it from other DC receptors. DC receptors such as
DC-SIGN are characterized by a rapid kinetics of internalization.
For example, FIG. 11 shows that anti-DC-SIGN/L.Doc internalizes
Alexa-labeled Coh.Flu M1 into GM-CSF/IFN cultured human DC
rapidly--most of the label is internal to the cells within 15 min.
In contrast, anti-DCIR.Doc internalizes the Coh.Flu M1 very
slowly--at 3 hours there is both significant amounts of internal
antigen and of cell-surface antigen. This result distinguishes DCIR
as a slow-internalizing DC receptor and is in contrast to the
conclusions of Bates et. al., who suggested that "Following
cross-linking, DCIR was only slowly and weakly internalized in
monocyte- and CD34-derived DC, in contrast to the rapid kinetics
observed with the MMR (data not shown). This finding suggests that
Ag capture by receptor-mediated endocytosis is not the principal
function of DCIR".
[0122] FIG. 11 shows that Coh.Flu M1 linked to anti-DCIR.Doc rAb
binds specifically to GM/IL-15 human DC. Monocyte-derived
GM-CSF/IL-15 cultured human DCs were incubated with the indicated
concentrations of anti-DCIR.Doc rAbs premixed for 1 hour with a
4-fold molar excess of biotinylated Coh.Flu M1. After 1 hour, cells
were washed and incubated with streptavidin-PE. After another wash,
the cells were analyzed by FACS to detect cell-associated PE. Green
plots are the Anti-DCIR.Doc rAbs, red curves are control IgG4.Doc
complexes.
[0123] FIG. 12 shows that the Coh.Flu M1 linked to
anti-DC-SIGN/L.Doc or anti-DCIR.Doc rAb binds and is internalized
into to GM-CSF/IL-4 human DC. Monocyte-derived GM-CSF/IL-4 cultured
human DCs were incubated with anti-DCIR.Doc or anti-DC-SIGN/L.Doc
rAb premixed for 1 hour with a 4-fold molar excess of Alexa-labeled
Coh.Flu M1. After 1 hour on ice, cells were washed and placed at 37
C. Confocal microscopy was used to analyze the cellular location of
cell-associated antigen (shown in red). Green marks cell
membrane-associated actin.
[0124] Targeting Coh.Flu M1 to human DC via DCIR.Doc identifies
DCIR as a superior receptor for vaccine development purposes.
Targeting Flu M1 antigen to human DC via the slow-internalizing
DCIR receptor was compared to targeting via fast-internalizing
ASGPR and LOX-1 receptors. The immune response monitored was
expansion of Flu M1-specific CD8+ T cells. The results show
targeting through DCIR is significantly more efficacious than via
LOX-1 or ASGPR. In a similar experiment, the superiority of
targeting via DCIR was even more evident when the DC were washed
free of residual [rAb.Doc:Coh.antigen] before culture with the CD8+
T cells. This situation is likely closer to the in vivo situation,
where targeted DC would move away from residual administered
antigen to encounter T cells in draining lymph nodes.
[0125] FIG. 13 shows that the Anti-DCIR.Doc:Coh.Flu complex is more
efficient at expanding Flu M1-specific CD8+ T cells than other
[anti-DC receptor rAbs.Doc:Coh.Flu M1] complexes. CD34-derived
CD1a+DCs, were co-cultured with CD8+ T cells and 8 nM (top panel)
or 0.8 nM (lower panel) of [anti-DCIR.sub.--2C9.Doc:Coh.Flu M1],
anti-LOX1.sub.--15C4.Doc, anti-ASGPR.sub.--49C11.Doc or IgG4.Doc
control rAb, each complexed with Coh.Flu M1. CD8+ T cells were then
analyzed for Flu M1-specific expansion. The inner boxes indicate
the percentages of tetramer-specific CD8+ T cells.
[0126] FIG. 14 shows that the Anti-DCIR.Doc:Coh.Flu complex
administered for 1 day is more efficient at expanding Flu
M1-specific CD8+ T cells than other [anti-DC receptor
rAbs.Doc:Coh.Flu M1] complexes. Study conditions were as for the
figure above, expect DC were washed at day 1 prior to addition of
autologous CD8+ T cells. Some anti-DCIR V regions are particularly
favorable to secretion of important antigens fused at the rAb H
chain C-terminus.
[0127] FIG. 15 shows that various antigens expressed as fusions to
the C-terminus of rAb H chain have intrinsic effects on the
secretion of rAb.antigen. Here identical antigen coding regions
were engineered on chimeric hIgG4 rAbs with two different mouse V
region specificities. These expression constructs were
co-transfected with appropriate L chain mouse V-region--hIgk
constructs into 293F cells and secretion of rAb was appraised after
three days. Some rAb antigens were well expressed, others
(including Flu HA5-1) very poorly. It should be expected that each
antigen has intrinsic biochemical properties affecting secretion in
the context of rAb. Indeed there is a strikingly parallel effect on
expression in the context of the two V region specificities
tested.
[0128] Flu HA5 is an antigen that is important to consider in
development of a vaccine against avian influenza. FIG. 16 shows the
unexpected discovery that different anti-DCIR V regions (derived
from different anti-DCIR mAbs) greatly affect secretion of the
desired anti-DCIR.Flu HA5 vaccine. In the example shown below,
DCIR.sub.--25A4 is particularly favorable for secretion of this
type of vaccine when compared to other DCIR V regions.
[0129] FIG. 16 shows the Anti-DCIR.Flu HA5 rAbs are secreted at
various efficiencies depending on the nature of the variable
regions. H and L chain expression plasmids encoding chimeric mouse
V region and human C region fused via the H chain C-terminus to
either Doc (Blue circles) or HA5-1 (Red triangles) were
co-transfected into 293 cells and after 3 days dilutions of the
supernatants were assayed for IgGFc by ELISA. Except for
DCIR.sub.--2C9, rAb.Docs were generally well expressed. However,
expression of rAb.HA5-1s varied widely.
[0130] The unique property of the anti-DCIR 25A4 V-regions to favor
secretion of rAb.HA5-1 illustrates application of claim 5. That is
based on our invention that a particular V-region can affect
secretion of a rAb.antigen. This means that intrinsic poor
secretion of a particular antigen in the context of a rAb fusion
protein can be overcome by screening different V regions with the
desired combining specificities for those favorable for secretion.
This is claimed as a new general principle for any secreted
rAb.fusion protein.
[0131] Anti-DCIR enhances priming of HIV specific CD8+ T cells.
FIG. 17 shows that anti-DCIR mAb has a particular action on
dendritic cells that enhances priming--that is the uptake of
peptide and its presentation on surface MHC to T cells specific to
the peptide antigen. The example shows that stimulation of DC with
anti-DCIR mAb together with CD40L, a known DC activation signal
usually delivered by cognate T cells, resulted in greatly increased
numbers of CD8+ T cells specific to the immunodominant HIV gag
peptide that was added to the DC culture. This property is highly
predictive for successful antigen targeting via anti-DC receptor
rAb vaccines and indicates that anti-DCIR.antigen vaccines will be
superior.
[0132] FIG. 17 shows that Anti-DCIR mAb enhances priming of HIV
antigen-specific CD8.sup.+ cells. Purified total CD8.sup.+ T cells
(2.times.10.sup.6 cells/well) were stimulated with autologous
IFN-DCs (1.times.10.sup.5 cells/well) and HLA-A201-restricted HIV
peptides pol (pol.sub.476-484 ILKEPVHGV (SEQ ID NO.: 54),
POl.sub.293-302 KYTAFTIPSI (SEQ ID NO.: 55)), and gag
(gag.sub.77-85, SLYNTVATL (SEQ ID NO.: 56), gag.sub.151-159,
TLNAWVKVV (SEQ ID NO.: 57)) (5 .mu.M). Cells were cultured for 9
days in 24 well plates that were pre-coated over night at 4c with 5
ug/well Anti-DCIR mAbs or control monoclonal antibodies diluted in
PBS pH9.6 and washed extensively. Cells were cultured in Yssel's
medium supplemented with 10% human AB serum, 10 U/ml IL-7 (R&D)
and 100 ng/ml CD40L (R&D). IL-2 was added at 10 U/ml at day 3.
Expansion of peptide-specific CD8.sup.+ T cells was determined by
counting the number of cells binding peptide/HLA-A201 tetramers
(Beckman Coulter) at the end of the culture period.
[0133] Anti-DCIR mAb enhances cross priming. FIG. 18 shows that
anti-DCIR mAb has a particular action on dendritic cells that
enhances cross-priming--that is the uptake of protein and its
correct processing and presentation on surface MHC as measured by
expansion of T cells specific to the antigen-derived peptide. The
example shows that stimulation of DC with anti-DCIR mAb together
with CD40L, a known DC activation signal usually delivered by
cognate T cells, resulted in greatly increased numbers of CD8+ T
cells specific to the immunodominant MART-1 epitope from the
Cohesin-MART-1 fusion protein that was added to the DC culture.
This property is highly desirable for antigen targeting via anti-DC
receptor rAb vaccines and indicates that anti-DCIR.antigen vaccines
will be superior.
[0134] FIG. 18 shows the Anti-DCIR mAb enhances priming of HIV
antigen-specific CD8+ cells. Above Figure method as for the
previous figure, except that coh.MART-1 peptide fusion protein
replaced peptide.
[0135] It is contemplated that any embodiment discussed in this
specification can be implemented with respect to any method, kit,
reagent, or composition of the invention, and vice versa.
Furthermore, compositions of the invention can be used to achieve
methods of the invention.
[0136] FIG. 19 shows an immunohistochemistry analysis of DCIR
distribution in human epithelial sheet. DR-FITC staining is shown
in green and PAB269 (DCIR)-568 is shown in red. The upper right
panel shows the images superimposed. Blue staining is DAPI for cell
nuclei. Digital imaging @ 40.times.. The cell morphology and DR
staining is characteristic of epidermal Langerhans cells--thus, the
analysis reveals DCIR expression on Langerhans cells--pointing to
the utility of DCIR to uptake anti-DCIR.antigen conjugate applied
to e.g. scarified skin. Therefore, these data shows that Langerhans
cells uptake of antigen associated with DC activation via adjuvant
will result in potent cellular responses against the targeted
antigen.
[0137] FIGS. 20A-20D shows monoclonal antibodies to DCIR Antigen,
specifically, affinity to DCIR.
[0138] Immobilization of DCIR Antigen:
[0139] DCIR antigen was immobilized onto AKT_iv covalent sensor
surfaces via the primary amines (50 ugmL-1 in 10 mM sodium acetate,
pH 5.5). The carboxylate surfaces were activated using a mixture of
EDC and NHS and DCIR was coupled to all four channels. Finally, any
remaining carboxylate groups were deactivated using a proprietary
blocking agent.
[0140] Determination of Affinities of Four Anti-DCIR Antibodies in
HBS:
[0141] To determine the affinities of four anti-DCIR antibodies,
dilution series of each antibody were prepared from 10 to 0.3125
.mu.g mL-1 and injected in parallel over immobilized DCIR antigen
for 180 s. Between sample injections the surfaces were regenerated
using two 60 s injections of 100 mM hydrochloric acid. Biosensor
measurements were performed on an Akubio acoustic biosensor.
TABLE-US-00002 TABLE 1 Kinetic Parameters calculated from the
interaction of four monoclonal antibodies with immobilized DCIR
antigen. Antibody k.sub.a (M.sup.-1s.sup.-1 .times. 10.sup.5
k.sub.d (s.sup.-1 .times. 10.sup.-4) K.sub.D (pM) Hybridoma Anti-
2.07 1.15 560 DCIR24A5.4A5 rAb Anti- 2.38 3.26 1370
DCIR24A5.4A5.DocVar1 C377 Hybridoma Anti- 5.56 4.70 850
DCIR29E9.2E2 rAb Anti- 1.50 2.90 1940 DCIR29E9.2E2.DocVar1 C409
[0142] Table 1 shows the high affinity DCIR ectodomain binding
properties of two preferred anti-DCIR monoclonal antibodies 24A5
and 9E8 and demonstrate that the derived mouse variable regions,
when grafted onto a human IgG4 body, largely retain the high
affinity binding properties. This data supports the specific claim
to the sequences [and their `humanized` derivatives] of these
variable regions regards utility for binding to human DCIR.
[0143] Cross-reactivity of anti-DCIR mAbs to Rhesus macaque DCIR.
To test the cross-reactivity of anti-human DCIR mAbs to Rhesus
macaque DCIR, 233F cells were transfected with Rhesus macaque DCIR
cDNA configured into a mammalian expression vector. The panel of
anti-human DCIR antibodies was tested via FACS for binding to
monkey DCIR compared to untransfected 293F cells and 293F cells
transfected with an identical vector directing the expression of
human DCIR. A comparison between the human and monkey DCIR
sequences is shown below. Those antibodies showing cross-reactivity
between human and monkey DCIR are particularly preferred since,
when configured e.g., as recombinant humanized anti-DCIR.antigen
vaccine, as a therapeutic agent, NHP toxicity studies can also
address mechanism-based issues [i.e., these testes can also address
efficacy relative to toxicity].
[0144] Human vs. Monkey DCIR. The primary sequence show is human
and changes seen in monkey DCIR are shown below the human sequence.
The putative transmembrane region is highlighted in underlined.
Non-conservative changes are shown highlighted in bold.
TABLE-US-00003 (SEQ ID NO.: 58)
MTSEITYAEVRFKNEFKSSGINTASSAASKERTAPHKSNTGFPKLLCASLLIFFLLLAISFFI
AFVIFFQKYSQLLEKKT (SEQ ID NO.: 59) MTSEITYAEV
RQNESKSSGIDSASSAASKKRTAPHKSNTGFSKLLCASLMIFFLLLAISFFFAFFIFFQKYS
QLLEKMT (SEQ ID NO.: 60)
TKELVHTTLECVKKNMPVEETAWSCCPKNWKSFSSNCYFISTESASWQDSEKDCARME
AHLLVINTQEEQDFIFQNLQEE (SEQ ID NO.: 61)
TKDLVHTTLECVKKNMTTEETAWSCCPKNWKPFSSNCYFISTESASWQKSEKDCARME
AHLLVINTREEQDFIFQNLQEE (SEQ ID NO.: 62)
SAYFVGLSDPEGQRHWQWVDQTPYNESSTFWHPREPSDPNERCVVLNFRKSPKRWGW
NDVNCLGPQRSVCEMMKIHL (SEQ ID NO.: 63)
SAYFVGLSDPEGQRHWQWVDQTPYNESSTFWHPHEPSDPDERCVVLNFRKTPKRWGW
NDVHCIVPQRSVCEMMKIHL
[0145] FIG. 21 shows the cross-reactivity of anti-DCIR mAbs to
Rhesus macaque DCIR. A sample FACS analysis is presented below.
Green plots show the background binding by control IgG4.gag
recombinant protein. The red plts are binding via anti-DCIR.gag
proteins [secondary antibody was PE-labeled antihuman IgGFc]. The
result shows comparable binding by 9E8 and 24A5 mAbs on 293F cells
transfected with human DCIR expression plasmid--on 293F cells
transfected with monkey DCIR expression plasmid, 9E8, but not 24A5,
bound. In a similar analysis mAbs 9E8, 29G10, 31A6, 3C2 bound well
to monkey DCIR, but mAbs 24A5, 6C8, 24E7, 5F9, 29E9 did not
bind.
[0146] FIG. 22 is a graph that shows the binding of DCIR ectodomain
to specific glycan structures. DCIR ectodomain was expressed as a
hIgGFc fusion protein secreted from 293F cells and was purified by
protein A affinity chromatography. The protein was tested for
binding of specific glycans using the version 3.0 of the printed
array from the Consortium for Functional Glycomics--this array
consists of 320 glycans (or glycoforms) in replicates of 6. The
Excel spread sheet shown below presents in columns A-F,
respectively, the Glycan number, the structure or name, the average
RFU value from the 6 replicates, the standard deviation, the
standard error of the mean (used for the error bars in the graph
above, which presents the entired data set) and % CV. Columns C--Y
contain the graph of glycan number vs. Average RFU, and Columns
Z-AE is the data from A-F sorted by RFU (high to low) to provide a
list of the Glycans bound with highest intensity. The highest and
lowest point from each set of six replicates has been removed so
the average is of 4 values rather than 6. This eliminates some of
the false hits that contain a single very high point. Thus, points
with high % CV should be considered suspect. The analysis was done
with detection using anti-human IgG-Fc that was labeled with
Phycoerythrin. The DCIR.IgFc was diluted in PBS to 200 .mu.g/ml
using Tris-saline binding buffer containing 2 mM Ca and Mg, 1% BSA
and 0.05% Tween 20.
[0147] This data was generated in collaboration with the Functional
Glycomics Consortium.
Neu5Ac.alpha.2-3Gal.beta.1-4GlcNAc.beta.1-2Man.alpha.1-3(Neu5Ac.alpha.2-3-
Gal.beta.1-4GlcNAc.beta.1-2Man.alpha.1-6)Man.beta.1-4GlcNAc.beta.1-4GlcNAc-
.beta.-Sp12 was the glycan which bound DCIR ectodomain most
tightly. Other hIgGFc fusion proteins tested did not show a
preference for this glycan which is a very complex carbohydrate
found on several human serum proteins.
[0148] Thus, antigen decorated with glycan 143, or a higher
affinity derivative screened from a panel of related structures,
should hone the antigen to DCIR and serve as a surrogate for the
anti-DCIR component of the DC-targeting vaccine or other DCIR
targeting agent. This could have cost benefit in vaccine
manufacture and storage.
TABLE-US-00004 TABLE 2 DCIR.IgGFc @ 200 ug/ml vs. anti-Human IgG PE
StDev SEM Avg w/o w/o w/o Glycan Max & Max & Max &
number Glycan name Min Min Min % CV 143
Neu5Ac.alpha.2-3Gal.beta.1-4GlcNAc.beta.1-2Man.alpha.1-3- 38314
2007 1004 5
4GlcNAc.beta.1-2Man.alpha.1-6)Man.beta.1-4GlcNAc.beta.1-
4GlcNAc.beta.-Sp12 173
GlcNAc.beta.1-4GlcNAc.beta.1-4GlcNAc.beta.-Sp8 17109 1865 932 11
172 (GlcNAc.beta.1-4)5.beta.-Sp8 11161 1247 624 11 45
[6OSO3]Gal.beta.1-4[6OSO3]Glc.beta.-Sp8 9762 1375 688 14 42
[6OSO3]Gal.beta.1-4Glc.beta.-Sp0 8376 3206 1603 38 15
.alpha.-Neu5Ac-Sp11 8128 887 443 11 92
GalNAc.beta.1-4GlcNAc.beta.-Sp0 8066 1278 639 16 47
[6OSO3]GlcNAc.beta.-Sp8 7906 2365 1183 30 1
Neu5Ac.alpha.2-8Neu5Ac.alpha.-Sp8 7738 1337 669 17 29
[3OSO3]Gal.beta.1-4(6OSO3)Glc.beta.-Sp0 7572 993 496 13 30
[3OSO3]Gal.beta.1-4(6OSO3)Glc.beta.-Sp8 7515 538 269 7 271
Fuc.alpha.1-2[6OSO3]Gal.beta.1-4[6OSO3]Glc-Sp0 7400 794 397 11 216
Neu5Ac.alpha.2-3Gal.beta.1-3(6OSO3)GlcNAc-Sp8 7334 3242 1621 44 26
[3OSO3][6OSO3]Gal.beta.1-4[6OSO3]GlcNAc.beta.-Sp0 7193 939 470 13
171 (GlcNAc.beta.1-4)6.beta.-Sp8 7154 1358 679 19 286
[3OSO3]Gal.beta.1-4[6OSO3]GlcNAc.beta.-Sp0 7146 1267 633 18 265
[3OSO3]Gal.beta.1-4(Fuc.alpha.1-3)(6OSO3)Glc-Sp0 7143 571 285 8 ***
Glycan #143 is
Neu5Ac.alpha.2-3Gal.beta.1-4GlcNAc.beta.1-2Man.alpha.1-3(Neu5Ac.alpha.2-3-
Gal.beta.1-4GlcNAc.beta.1-2Man.alpha.1-6)Man.beta.1-4GlcNAc.beta.1-4GlcNAc-
.beta.-Sp12.
[0149] FIG. 23A to 23C show that DCIR is a global target for all
blood DC subsets. Two subsets of DCs are identified in the blood:
CD11c.sup.+mDCs and BDCA2.sup.+pDCs. DCIR is one of the rare
lectin-type receptors found on both DC subsets. mDCs and pDCs were
purified from cytapheresis and each DC subset was cultured with
autologous purified CD8.sup.+ T cells and decreasing concentrations
of four recombinant forms of Flu-MP: Flu-MP, Flu-MP fused to IgG4
and Flu-MP fused to two different recombinant anti-DCIR antibodies:
24A5 and 9E8.
[0150] Results shown in FIG. 23A below indicate that both
recombinant DCIR-Flu-MP fusion proteins can potently target Flu-MP
to mDC as the two proteins can induce between 1.78% and 2.18%
tetramer positive cells at a concentration as low as 80 pM, a point
where Flu-MP itself and the IgG4-Flu-MP are not able to induce
expansion of antigen-specific T cells. pDCs were also able to
crosspresent the four forms of recombinant Flu-MP at 8 nM. At 0.8
nM and 80 pM, two DCIR-Flu-MP constructs were crosspresented but
the two other Flu-MP constructs were not (FIG. 23B below).
[0151] Taken together, these data indicate that DCIR potently
target proteins for crosspresentation by both blood mDCs and pDC.
In human LCs and IntDCs have capacity to preferentially,
respectively, prime cellular immunity and humoral immunity.
Targeting antigen to a pan-DC molecule, like DCIR, will potentially
induce a wide humoral and cellular immune response by targeting
various DC subsets. This is in contrast to a subset-specific
antigen-delivery vehicle such as anti-Langerin.
[0152] FIG. 23A shows blood-derived mDCs from HLA-A2 donor are
targeted with 8 nM, 0.8 nM or 80 pM each of aDCIR-Flu-MP (a#24A5
and b#9E8), IgG4-Flu-MP, or Flu-MP, matured with CD40L and
co-cultured with autologous CD8.sup.+ T cells. 10 d later, T cell
expansion evaluated by specific HLA-A2-M1 tetramer staining
[vertical axis].
[0153] FIG. 23B shows blood-derived pDCs from HLA-A2 donor are
targeted with 8 nM, 0.8 nM or 80 pM each of aDCIR-Flu-MP (a #24A5
and b #9E8), IgG4:Flu-MP, or Flu-MP, matured with CD40L and
co-cultured with autologous CD8.sup.+ T cells. 10 d later, T cell
expansion evaluated by specific HLA-A2-M1 tetramer staining
[vertical axis].
[0154] FIG. 23C shows DCIR allows crosspresentation of proteins by
LCs and dermal CD14.sup.+DCs. Skin-derived DC from HLA-A2 donor are
targeted with 8 nM each of anti-DCIR:Flu-MP, anti-Langerin:Flu-MP
or IgG4:Flu-MP, matured with CD40L and co-cultured with autologous
CD8.sup.+ T cells. 10 d later, T cell expansion was evaluated by
specific HLA-A2-M1 tetramer staining [vertical axis].
[0155] FIG. 24 shows that demonstrate that vaccination with
DCIR-FluM1 permits generation of FluM1 specific recall CD8+ T cell
immunity. The results from sublethally irradiated NOD/SCID
.beta.2m-/- immunodeficient mice were transplanted with
3.times.10.sup.6 CD34+ HPCs from HLA-A*0201+ healthy donors, and at
4-8 weeks post transplantation reconstituted by adoptive transfer
of 20.times.106 autologous T cells. Mice were pre-treated for 10
days with five doses of human recombinant FLT3-ligand (FLT3-L) to
mobilize DCs. A total of 30 mcg DCIR-FluM1 vaccine was delivered in
two sites: i.p. and i.v. at two time points, i.e, day 1 and day 7
with 50 mcg/mouse poly IC as adjuvant. Induction of
influenza-specific immune response was assessed by staining blood
and tissues with matrix protein 1: FluM158-66 (GILGFVFTL) (SEQ ID
NO.: 64) peptide-loaded tetramer. As shown in FIG. 24, 4/5 mice
vaccinated with DCIR-FluM1 demonstrated, at day 11 post
vaccination, circulating human CD8+ T cells binding FluM1 tetramer:
0.63%, 0.34%, 0.21%, and 0.62%. Staining with control tetramer
loaded with HIV gag peptide was nearly negative. These preliminary
results were confirmed in independent cohorts of mice and the
expansion of high affinity FluM1 tetramer-binding CD8+ T cells was
observed in a total of 9/12 vaccinated mice. These results
demonstrate that vaccination with DCIR-FluM1 permits generation of
FluM1 specific recall CD8+ T cell immunity.
[0156] It will be understood that particular embodiments described
herein are shown by way of illustration and not as limitations of
the invention. The principal features of this invention can be
employed in various embodiments without departing from the scope of
the invention. Those skilled in the art will recognize, or be able
to ascertain using no more than routine experimentation, numerous
equivalents to the specific procedures described herein. Such
equivalents are considered to be within the scope of this invention
and are covered by the claims.
[0157] All publications and patent applications mentioned in the
specification are indicative of the level of skill of those skilled
in the art to which this invention pertains. All publications and
patent applications are herein incorporated by reference to the
same extent as if each individual publication or patent application
was specifically and individually indicated to be incorporated by
reference.
[0158] The use of the word "a" or "an" when used in conjunction
with the term "comprising" in the claims and/or the specification
may mean "one," but it is also consistent with the meaning of "one
or more," "at least one," and "one or more than one." The use of
the term "or" in the claims is used to mean "and/or" unless
explicitly indicated to refer to alternatives only or the
alternatives are mutually exclusive, although the disclosure
supports a definition that refers to only alternatives and
"and/or." Throughout this application, the term "about" is used to
indicate that a value includes the inherent variation of error for
the device, the method being employed to determine the value, or
the variation that exists among the study subjects.
[0159] As used in this specification and claim(s), the words
"comprising" (and any form of comprising, such as "comprise" and
"comprises"), "having" (and any form of having, such as "have" and
"has"), "including" (and any form of including, such as "includes"
and "include") or "containing" (and any form of containing, such as
"contains" and "contain") are inclusive or open-ended and do not
exclude additional, unrecited elements or method steps.
[0160] The term "or combinations thereof" as used herein refers to
all permutations and combinations of the listed items preceding the
term. For example, "A, B, C, or combinations thereof" is intended
to include at least one of: A, B, C, AB, AC, BC, or ABC, and if
order is important in a particular context, also BA, CA, CB, CBA,
BCA, ACB, BAC, or CAB. Continuing with this example, expressly
included are combinations that contain repeats of one or more item
or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so
forth. The skilled artisan will understand that typically there is
no limit on the number of items or terms in any combination, unless
otherwise apparent from the context.
[0161] All of the compositions and/or methods disclosed and claimed
herein can be made and executed without undue experimentation in
light of the present disclosure. While the compositions and methods
of this invention have been described in terms of preferred
embodiments, it will be apparent to those of skill in the art that
variations may be applied to the compositions and/or methods and in
the steps or in the sequence of steps of the method described
herein without departing from the concept, spirit and scope of the
invention. All such similar substitutes and modifications apparent
to those skilled in the art are deemed to be within the spirit,
scope and concept of the invention as defined by the appended
claims.
REFERENCES
[0162] Banchereau, J., F. Briere, et al. (2000). "Immunobiology of
dendritic cells." Annu Rev Immunol 18: 767-811. [0163] Banchereau,
J., A. K. Palucka, et al. (2001). "Immune and clinical responses in
patients with metastatic melanoma to CD34(+) progenitor-derived
dendritic cell vaccine." Cancer Res 61(17): 6451-8. [0164]
Banchereau, J., B. Schuler-Thurner, et al. (2001). "Dendritic cells
as vectors for therapy." Cell 106(3): 271-4. [0165] Bates, E. E.,
N. Fournier, et al. (1999). "APCs express DCIR, a novel C-type
lectin surface receptor containing an immunoreceptor tyrosine-based
inhibitory motif." J Immunol 163(4): 1973-83. [0166] Bendtsen, J.
D., H. Nielsen, et al. (2004). "Improved prediction of signal
peptides: SignalP 3.0." J Mol Biol 340(4): 783-95. [0167] Berard,
F., P. Blanco, et al. (2000). "Cross-priming of naive CD8 T cells
against melanoma antigens using dendritic cells loaded with killed
allogeneic melanoma cells." J Exp Med 192(11): 1535-44. [0168]
Bonifaz, L. C., D. P. Bonnyay, et al. (2004). "In vivo targeting of
antigens to maturing dendritic cells via the DEC-205 receptor
improves T cell vaccination." J Exp Med 199(6): 815-24. [0169]
Carvalho, A. L., F. M. Dias, et al. (2003). "Cellulosome assembly
revealed by the crystal structure of the cohesin-dockerin complex."
Proc Natl Acad Sci USA 100(24): 13809-14. [0170] Cella, M., F.
Sallusto, et al. (1997). "Origin, maturation and antigen presenting
function of dendritic cells." Curr Opin Immunol 9(1): 10-6. [0171]
Delneste, Y., G. Magistrelli, et al. (2002). "Involvement of LOX-1
in dendritic cell-mediated antigen cross-presentation." Immunity
17(3): 353-62. [0172] Figdor, C. G., Y. van Kooyk, et al. (2002).
"C-type lectin receptors on dendritic cells and Langerhans cells."
Nat Rev Immunol 2(2): 77-84. [0173] Geijtenbeek, T. B., S. J. van
Vliet, et al. (2004). "Self- and nonself-recognition by C-type
lectins on dendritic cells." Annu Rev Immunol 22: 33-54. [0174]
Gerwig, G. J., J. P. Kamerling, et al. (1993). "The nature of the
carbohydrate-peptide linkage region in glycoproteins from the
cellulosomes of Clostridium thermocellum and Bacteroides
cellulosolvens." J Biol Chem 268(36): 26956-60. [0175] Mellman, I.
and R. M. Steinman (2001). "Dendritic cells: specialized and
regulated antigen processing machines." Cell 106(3): 255-8. [0176]
Neidhardt-Berard, E. M., F. Berard, et al. (2004). "Dendritic cells
loaded with killed breast cancer cells induce differentiation of
tumor-specific cytotoxic T lymphocytes." Breast Cancer Res 6(4):
R322-8. [0177] Orban, J., P. Alexander, et al. (1992).
"Sequence-specific .sup.1H NMR assignments and secondary structure
of the streptococcal protein G B2-domain." Biochemistry 31(14):
3604-11. [0178] Palucka, A. K., J. Gatlin, et al. (2003). "Human
dendritic cell subsets in NOD/SCID mice engrafted with CD34+
hematopoietic progenitors." Blood 102(9): 3302-10. [0179]
Ramakrishna, V., J. F. Treml, et al. (2004). "Mannose receptor
targeting of tumor antigen pmel17 to human dendritic cells directs
anti-melanoma T cell responses via multiple HLA molecules." J
Immunol 172(5): 2845-52. [0180] Reddy, M. P., C. A. Kinney, et al.
(2000). "Elimination of Fc receptor-dependent effector functions of
a modified IgG4 monoclonal antibody to human CD4." J Immunol
164(4): 1925-33. [0181] Shortman, K. and Y. J. Liu (2002). "Mouse
and human dendritic cell subtypes." Nat Rev Immunol 2(3): 151-61.
[0182] Shulman, M., C. D. Wilde, et al. (1978). "A better cell line
for making hybridomas secreting specific antibodies." Nature
276(5685): 269-70. [0183] Steinman, R. M. and M. Dhodapkar (2001).
"Active immunization against cancer with dendritic cells: the near
future." Int J Cancer 94(4): 459-73. [0184] Tacken, P. J., I. J. de
Vries, et al. (2005). "Effective induction of naive and recall
T-cell responses by targeting antigen to human dendritic cells via
a humanized anti-DC-SIGN antibody." Blood 106(4): 1278-85. [0185]
Trombetta, E. S, and I. Mellman (2005). "Cell biology of antigen
processing in vitro and in vivo." Annu Rev Immunol 23: 975-1028.
[0186] Trumpfheller, C., J. S. Finke, et al. (2006). "Intensified
and protective CD4+ T cell immunity in mice with anti-dendritic
cell HIV gag fusion antibody vaccine." J Exp Med 203(3): 607-17.
Sequence CWU 1
1
64173PRTArtificialSynthetic peptide. 1Met Glu Trp Thr Trp Val Phe
Leu Phe Leu Leu Ser Val Thr Ala Gly 1 5 10 15 Val His Ser Gln Val
Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys 20 25 30 Pro Gly Ala
Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe 35 40 45 Ser
Ser Tyr Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu 50 55
60 Glu Trp Ile Gly Glu Ile Leu Pro Gly 65 70
273PRTArtificialSynthetic peptide. 2Met Glu Trp Thr Trp Val Phe Leu
Phe Leu Leu Ser Val Thr Ala Gly 1 5 10 15 Val His Ser Gln Val Gln
Leu Gln Gln Ser Gly Thr Glu Leu Met Lys 20 25 30 Pro Gly Ala Ser
Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe 35 40 45 Ser Thr
Tyr Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu 50 55 60
Glu Trp Ile Gly Glu Ile Leu Pro Gly 65 70 373PRTArtificialSynthetic
peptide. 3Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala
Thr Asp 1 5 10 15 Val His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala
Glu Leu Val Lys 20 25 30 Pro Gly Ala Ser Val Lys Leu Ser Cys Lys
Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Ser Tyr Trp Met His Trp Val
Lys Gln Arg Pro Gly Glu Gly Leu 50 55 60 Glu Trp Ile Gly Glu Ile
Asn Pro Ser 65 70 473PRTArtificialSynthetic peptide. 4Met Glu Cys
Asn Trp Ile Leu Pro Phe Ile Leu Ser Val Ile Ser Gly 1 5 10 15 Val
Tyr Ser Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg 20 25
30 Pro Gly Ala Ser Val Asn Met Ser Cys Lys Ala Ala Gly Tyr Ser Phe
35 40 45 Thr Ser Tyr Trp Val Tyr Trp Val Lys Gln Arg Pro Gly Gln
Gly Leu 50 55 60 Glu Trp Ile Gly Ala Ile Tyr Pro Lys 65 70
573PRTArtificialSynthetic peptide. 5Met Lys Cys Ser Trp Val Ile Phe
Phe Leu Met Ala Val Val Thr Gly 1 5 10 15 Val Asn Ser Glu Val Gln
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg 20 25 30 Pro Gly Ala Leu
Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile 35 40 45 Asn Asp
Tyr Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu 50 55 60
Glu Arg Ile Gly Trp Ile Asp Pro Asp 65 70 673PRTArtificialSynthetic
peptide. 6Met Asp Trp Leu Trp Asn Leu Leu Phe Leu Met Ala Ala Ala
Gln Ser 1 5 10 15 Ala Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro
Glu Leu Lys Lys 20 25 30 Pro Gly Glu Thr Val Lys Ile Ser Cys Lys
Ala Ser Gly Tyr Ser Phe 35 40 45 Thr Asn Tyr Gly Met Asn Trp Val
Lys Gln Ala Pro Gly Lys Gly Leu 50 55 60 Lys Trp Met Gly Trp Ile
Asn Thr Tyr 65 70 775PRTArtificialSynthetic peptide. 7Met Asn Arg
Leu Thr Ser Ser Leu Leu Leu Leu Ile Val Pro Ala Tyr 1 5 10 15 Val
Leu Ser Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln 20 25
30 Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu
35 40 45 Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser
Gly Lys 50 55 60 Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp 65 70
75 875PRTArtificialSynthetic peptide. 8Met Asn Arg Leu Thr Ser Ser
Leu Leu Leu Leu Ile Val Pro Ala Tyr 1 5 10 15 Val Leu Ser Gln Val
Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln 20 25 30 Pro Ser Gln
Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu 35 40 45 Ser
Thr Ser Gly Met Gly Leu Ser Trp Ile Arg Gln Pro Ser Gly Lys 50 55
60 Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp 65 70 75
968PRTArtificialSynthetic peptide. 9Ser Gly Arg Thr Asn Asp Asn Glu
Lys Phe Lys Gly Lys Ala Thr Phe 1 5 10 15 Thr Ala Asp Thr Ser Ser
Lys Lys Ala Tyr Met Gln Leu Ser Ser Leu 20 25 30 Thr Ser Glu Asp
Ser Ala Val Tyr Tyr Cys Ala Arg Arg Gly Gly Tyr 35 40 45 Ser Phe
Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala 50 55 60
Lys Thr Lys Gly 65 1068PRTArtificialSynthetic peptide. 10Ser Gly
Arg Thr Asn Asp Asn Glu Lys Phe Lys Gly Lys Ala Thr Ile 1 5 10 15
Thr Ala Asp Thr Ser Ser Lys Lys Ala Tyr Met Gln Leu Ser Ser Leu 20
25 30 Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Arg Gly Gly
Tyr 35 40 45 Ser Phe Ala Phe Trp Gly Gln Gly Thr Leu Val Ser Val
Ser Ala Ala 50 55 60 Lys Thr Lys Gly 65 1170PRTArtificialSynthetic
peptide. 11Tyr Gly Arg Thr Asp Tyr Asn Gly Lys Phe Lys Asn Lys Ala
Thr Leu 1 5 10 15 Thr Val Ala Lys Ser Ser Ser Thr Ala Tyr Met Gln
Leu Ser Ser Leu 20 25 30 Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
Ala Arg Gly Asp Tyr Tyr 35 40 45 Gly Ser Ser Phe Ala Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val Ser 50 55 60 Ala Ala Lys Thr Lys Gly 65
70 1268PRTArtificialSynthetic peptide. 12Asn Ser Arg Thr Ser Tyr
Asn Gln Lys Phe Gln Asp Lys Ala Thr Leu 1 5 10 15 Thr Ala Val Thr
Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu 20 25 30 Thr Asn
Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Pro His Tyr Asp 35 40 45
Leu Phe Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala 50
55 60 Lys Thr Lys Gly 65 1368PRTArtificialSynthetic peptide. 13Asn
Ser Arg Thr Ser Tyr Asn Gln Lys Phe Gln Asp Lys Ala Thr Leu 1 5 10
15 Thr Ala Val Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu
20 25 30 Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Pro His
Tyr Asp 35 40 45 Ser Phe Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ala Ala 50 55 60 Lys Thr Lys Gly 65
1472PRTArtificialSynthetic peptide. 14Asn Gly Asn Thr Ile Tyr Asp
Pro Lys Phe Gln Gly Lys Ala Ser Ile 1 5 10 15 Thr Ala Asp Thr Ser
Pro Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu 20 25 30 Thr Ser Glu
Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Arg Ser Pro 35 40 45 Met
Val Thr Thr Gly Phe Val Tyr Trp Gly Gln Gly Thr Val Val Thr 50 55
60 Val Ser Ala Ala Lys Thr Lys Gly 65 70 1570PRTArtificialSynthetic
peptide. 15Thr Gly Glu Ser Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe
Ala Phe 1 5 10 15 Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln
Ile Ser Asn Leu 20 25 30 Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys
Ala Arg Gly Asp Phe Arg 35 40 45 Tyr Tyr Tyr Phe Asp Tyr Trp Gly
Gln Gly Thr Thr Leu Thr Gly Ser 50 55 60 Ser Ala Lys Thr Lys Gly 65
70 1674PRTArtificialSynthetic peptide. 16Asp Asp Lys Arg Tyr Asn
Pro Ser Leu Lys Ser Arg Leu Thr Ile Phe 1 5 10 15 Lys Asp Pro Ser
Ser Asn Gln Val Phe Leu Arg Ile Thr Ser Val Asp 20 25 30 Thr Ala
Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Asn Ser His Tyr Tyr 35 40 45
Gly Ser Thr Tyr Gly Gly Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr 50
55 60 Val Thr Val Ser Ser Ala Lys Thr Lys Gly 65 70
1774PRTArtificialSynthetic peptide. 17Asp Asp Lys Arg Tyr Asn Pro
Ser Leu Lys Ser Arg Leu Thr Ile Ser 1 5 10 15 Lys Asp Thr Ser Ser
Asn Gln Val Phe Leu Lys Ile Thr Ile Val Asp 20 25 30 Thr Ala Asp
Ala Ala Thr Tyr Tyr Cys Ala Arg Ser Ser His Tyr Tyr 35 40 45 Gly
Tyr Gly Tyr Gly Gly Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr 50 55
60 Val Thr Val Ser Ser Ala Lys Thr Lys Gly 65 70
1862PRTArtificialSynthetic peptide. 18Met Glu Thr Asp Thr Leu Leu
Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp
Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30 Val Ser Leu
Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45 Val
Asp Ser Tyr Gly Ile Ser Phe Met His Trp Tyr Gln Gln 50 55 60
1962PRTArtificialSynthetic peptide. 19Met Glu Thr Asp Thr Leu Leu
Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp
Ile Val Leu Ile Gln Ser Pro Ala Ser Leu Ala 20 25 30 Val Ser Leu
Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45 Val
Asp Ser Tyr Val Asn Ser Phe Met His Trp Tyr Gln Gln 50 55 60
2062PRTArtificialSynthetic peptide. 20Met Glu Thr Asp Thr Leu Leu
Leu Trp Val Leu Leu Leu Gly Val Pro 1 5 10 15 Gly Ser Thr Gly Asn
Ile Val Leu Thr Gln Ser Pro Thr Ser Phe Thr 20 25 30 Val Ser Leu
Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45 Val
His Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln 50 55 60
2162PRTArtificialSynthetic peptide. 21Met Glu Thr Asp Thr Leu Leu
Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asn
Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30 Val Ser Leu
Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45 Ile
His Ser Tyr Gly Asn Ser Phe Leu His Trp Tyr Gln Gln 50 55 60
2259PRTArtificialChemically synthesized peptide 22Met Asp Phe Arg
Val Gln Ile Phe Ser Phe Leu Leu Met Ser Ala Ser 1 5 10 15 Val Ile
Met Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Leu 20 25 30
Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser 35
40 45 Ser Asn Ile Ser Tyr Met Tyr Trp Tyr Gln Gln 50 55
2359PRTArtificialSynthetic peptide. 23Met Asp Phe Gln Val Gln Ile
Phe Ser Phe Leu Leu Met Ser Ala Ser 1 5 10 15 Val Ile Met Ser Arg
Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Leu 20 25 30 Met Ser Ala
Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser 35 40 45 Ser
Asn Ile Ser Tyr Met Tyr Trp Tyr Gln Gln 50 55
2459PRTArtificialSynthetic peptide. 24Met Ser Val Leu Thr Gln Val
Leu Ala Leu Leu Leu Leu Trp Leu Thr 1 5 10 15 Gly Ala Arg Cys Asp
Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser 20 25 30 Ala Ser Val
Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn 35 40 45 Ile
His Asn Tyr Leu Ala Trp Tyr Gln Gln Glu 50 55
2558PRTArtificialSynthetic peptide. 25Met Ser Val Leu Thr Gln Val
Leu Ala Leu Leu Leu Leu Trp Leu Thr 1 5 10 15 Gly Ala Arg Cys Asp
Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser 20 25 30 Ala Ser Val
Gly Glu Thr Val Thr Ile Thr Cys Arg Thr Ser Gly Asn 35 40 45 Ile
Arg Asn Tyr Leu Ala Trp Tyr Gln Gln 50 55
2660PRTArtificialSynthetic peptide. 26Met Thr Met Phe Ser Leu Ala
Leu Leu Leu Ser Leu Leu Leu Leu Cys 1 5 10 15 Val Ser Asp Ser Arg
Ala Glu Thr Thr Val Thr Gln Ser Pro Ala Ser 20 25 30 Leu Ser Met
Ala Ile Gly Glu Lys Val Thr Ile Arg Cys Val Thr Ser 35 40 45 Thr
Asp Ile Asp Asp Asp Val Asn Trp Tyr Gln Gln 50 55 60
2760PRTArtificialSynthetic peptide. 27Met Thr Met Phe Ser Leu Ala
Leu Leu Leu Ser Leu Leu Leu Leu Cys 1 5 10 15 Val Ser Asp Ser Arg
Ala Glu Thr Thr Val Thr Gln Ser Pro Ala Ser 20 25 30 Leu Ser Met
Ala Ile Gly Glu Lys Val Thr Ile Arg Cys Val Thr Ser 35 40 45 Thr
Asp Ile Asp Asp Asp Val Asn Trp Tyr Gln Gln 50 55 60
2866PRTArtificialSynthetic peptide. 28Lys Pro Gly Gln Pro Pro Lys
Leu Leu Ile Tyr Arg Ala Ser Asn Gln 1 5 10 15 Glu Ser Gly Ile Pro
Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp 20 25 30 Phe Thr Leu
Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr 35 40 45 Tyr
Cys Gln Gln Ser Asn Glu Asp Pro Leu Thr Phe Gly Ala Gly Thr 50 55
60 Lys Leu 65 2966PRTArtificialSynthetic peptide. 29Lys Pro Gly Gln
Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Gln 1 5 10 15 Glu Ser
Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp 20 25 30
Phe Thr Pro Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr 35
40 45 Tyr Cys Gln Gln Ser Asn Glu Asp Pro Leu Thr Phe Gly Ala Gly
Thr 50 55 60 Lys Leu 65 3066PRTArtificialSynthetic peptide. 30Lys
Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Val Ser Asn Leu 1 5 10
15 Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp
20 25 30 Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala
Thr Tyr 35 40 45 Tyr Cys Gln Gln Ser Asn Glu Asp Pro Phe Thr Phe
Gly Ser Gly Thr 50 55 60 Lys Leu 65 3166PRTArtificialSynthetic
peptide. 31Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser
Asn Val 1 5 10 15 Glu Ser Gly Val Pro Ala Lys Phe Ser Gly Ser Gly
Ser Arg Thr Asp 20 25 30 Phe Thr Leu Thr Ile Asp Pro Val Glu Ala
Asp Asp Ala Ala Thr Tyr 35 40 45 Tyr Cys Gln Gln Asn Ser Glu Asp
Pro Trp Thr Phe Gly Gly Gly Thr 50 55 60 Lys Leu 65
3266PRTArtificialSynthetic peptide. 32Lys Pro Gly Gln Pro Pro Lys
Leu Leu Ile Tyr Leu Ala Ser Asn Val 1 5 10 15 Glu Ser Gly Val Pro
Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp 20 25 30
Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr 35
40 45 Tyr Cys Gln Gln Asn Ser Glu Asp Pro Trp Thr Phe Gly Gly Gly
Thr 50 55 60 Lys Leu 65 3366PRTArtificialSynthetic peptide. 33Lys
Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu 1 5 10
15 Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp
20 25 30 Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Asp Asp Ala Ala
Thr Tyr 35 40 45 Tyr Cys Gln Gln Asn Asn Glu Asp Pro Trp Thr Phe
Gly Gly Gly Thr 50 55 60 Lys Leu 65 3466PRTArtificialSynthetic
peptide. 34Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile Tyr Leu Thr Ser
Asn Leu 1 5 10 15 Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly
Ser Gly Thr Ser 20 25 30 Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala
Glu Asp Ala Ala Thr Tyr 35 40 45 Tyr Cys Gln Gln Trp Ser Ser Asn
Pro Pro Thr Phe Gly Ala Gly Thr 50 55 60 Lys Leu 65
3566PRTArtificialSynthetic peptide. 35Lys Pro Arg Ser Ser Pro Lys
Pro Trp Ile Tyr Leu Thr Ser Asn Leu 1 5 10 15 Ala Ser Gly Val Pro
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser 20 25 30 Tyr Ser Leu
Thr Thr Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr 35 40 45 Cys
Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr Phe Gly Ala Gly Thr 50 55
60 Lys Leu 65 3665PRTArtificialSynthetic peptide. 36Lys Gln Gly Lys
Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu 1 5 10 15 Ala Asp
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln 20 25 30
Tyr Ser Leu Lys Ile Asn Thr Leu Gln Pro Glu Asp Phe Gly Ser Tyr 35
40 45 Tyr Cys Gln His Phe Trp Asp Ser Trp Thr Phe Gly Gly Gly Thr
Lys 50 55 60 Leu 65 3766PRTArtificialSynthetic peptide. 37Lys Gln
Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu 1 5 10 15
Ala Asp Gly Val Pro Ser Arg Phe Gly Gly Ser Gly Ser Gly Thr Gln 20
25 30 Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Asn
Tyr 35 40 45 Tyr Cys Gln His Phe Trp Ser Ser Pro Tyr Thr Phe Gly
Gly Gly Thr 50 55 60 Lys Leu 65 3866PRTArtificialSynthetic peptide.
38Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile Ser Glu Gly Asn Thr Leu 1
5 10 15 Arg Pro Gly Val Pro Ser Arg Phe Ser Ser Ser Gly Tyr Gly Thr
Asp 20 25 30 Phe Val Phe Thr Ile Glu Asn Met Leu Ser Glu Asp Val
Ala Asp Tyr 35 40 45 Tyr Cys Leu Gln Ser Gly Asn Leu Pro Tyr Thr
Phe Gly Gly Gly Thr 50 55 60 Lys Leu 65 3966PRTArtificialSynthetic
peptide. 39Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile Ser Glu Gly Asn
Thr Leu 1 5 10 15 Arg Ala Gly Val Pro Ser Arg Phe Ser Ser Ser Gly
Tyr Gly Thr Asp 20 25 30 Phe Val Phe Thr Ile Glu Asn Met Leu Ser
Glu Asp Val Ala Asp Tyr 35 40 45 Tyr Cys Leu Gln Ser Gly Asn Leu
Pro Tyr Thr Phe Gly Gly Gly Thr 50 55 60 Lys Leu 65
4071PRTArtificialSynthetic peptide. 40Ala Ser Asp Thr Thr Glu Ala
Arg His Pro His Pro Pro Val Thr Thr 1 5 10 15 Pro Thr Thr Asp Arg
Lys Gly Thr Thr Ala Glu Glu Leu Ala Gly Ile 20 25 30 Gly Ile Leu
Thr Val Ile Leu Gly Gly Lys Arg Thr Asn Asn Ser Thr 35 40 45 Pro
Thr Lys Gly Glu Phe Cys Arg Tyr Pro Ser His Trp Arg Pro Leu 50 55
60 Glu His His His His His His 65 70 4111PRTArtificialSynthetic
peptide. 41Gly Gly Ser Gly Gly Ser Gly Gly Ser Leu Asp 1 5 10
4236DNAArtificialSynthetic oligonucleotide. 42ggatggtggg aagatggata
cagttggtgc agcatc 364348DNAArtificialSynthetic oligonucleotide.
43ctaggaacag tcagcacggg acaaactctt ctccacagtg tgaccttc
484437DNAArtificialSynthetic oligonucleotide. 44gtcactggct
cagggaaata gcccttgacc aggcatc 374531DNAArtificialSynthetic
oligonucleotide. 45ccaggcatcc tagagtcacc gaggagccag t
314638DNAArtificialSynthetic oligonucleotide. 46ggtgctggag
gggacagtca ctgagctgct catagtgt 3847107DNAArtificialSynthetic
oligonucleotide. 47ctagttgctg gctaatggac cccaaaggct ccctttcctg
gagaatactt ctgtttctct 60ccctggcttt tgagttgtcg tacggattaa ttaagggccc
actcgag 10748100DNAArtificialSynthetic oligonucleotide.
48ctagttgctg gctaatggac cccaaaggct ccctttcctg gagaatactt ctgtttctct
60ccctggcttt tgagttgtcg tacggattaa ttaagggccc
1004946DNAArtificialSynthetic oligonucleotide. 49gctagcgata
caacagaacc tgcaacacct acaacacctg taacaa
465029DNAArtificialSynthetic oligonucleotide. 50caccatcacc
atcaccattg agcggccgc 295170DNAArtificialSynthetic oligonucleotide.
51gctagcgata caacagaacc tgcaacacct acaacacctg taacaacacc gacaacaaca
60cttctagcgc 7052119DNAArtificialSynthetic oligonucleotide.
52gctagcccca ttctgagccc cctgaccaaa ggcattctgg gctttgtgtt taccctgacc
60gtgcccagcg aacgcaaggg tatacttgga ttcgttttca cacttactta agcggccgc
119539PRTArtificialSynthetic peptide. 53Gly Ile Leu Gly Phe Val Phe
Thr Leu 1 5 549PRTArtificialSynthetic peptide. 54Ile Leu Lys Glu
Pro Val His Gly Val 1 5 5510PRTArtificialSynthetic peptide. 55Lys
Tyr Thr Ala Phe Thr Ile Pro Ser Ile 1 5 10
569PRTArtificialSynthetic peptide. 56Ser Leu Tyr Asn Thr Val Ala
Thr Leu 1 5 579PRTArtificialSynthetic peptide. 57Thr Leu Asn Ala
Trp Val Lys Val Val 1 5 5880PRTArtificialSynthetic peptide. 58Met
Thr Ser Glu Ile Thr Tyr Ala Glu Val Arg Phe Lys Asn Glu Phe 1 5 10
15 Lys Ser Ser Gly Ile Asn Thr Ala Ser Ser Ala Ala Ser Lys Glu Arg
20 25 30 Thr Ala Pro His Lys Ser Asn Thr Gly Phe Pro Lys Leu Leu
Cys Ala 35 40 45 Ser Leu Leu Ile Phe Phe Leu Leu Leu Ala Ile Ser
Phe Phe Ile Ala 50 55 60 Phe Val Ile Phe Phe Gln Lys Tyr Ser Gln
Leu Leu Glu Lys Lys Thr 65 70 75 80 5979PRTArtificialSynthetic
peptide. 59Met Thr Ser Glu Ile Thr Tyr Ala Glu Val Arg Gln Asn Glu
Ser Lys 1 5 10 15 Ser Ser Gly Ile Asp Ser Ala Ser Ser Ala Ala Ser
Lys Lys Arg Thr 20 25 30 Ala Pro His Lys Ser Asn Thr Gly Phe Ser
Lys Leu Leu Cys Ala Ser 35 40 45 Leu Met Ile Phe Phe Leu Leu Leu
Ala Ile Ser Phe Phe Phe Ala Phe 50 55 60 Phe Ile Phe Phe Gln Lys
Tyr Ser Gln Leu Leu Glu Lys Met Thr 65 70 75
6080PRTArtificialSynthetic peptide. 60Thr Lys Glu Leu Val His Thr
Thr Leu Glu Cys Val Lys Lys Asn Met 1 5 10 15 Pro Val Glu Glu Thr
Ala Trp Ser Cys Cys Pro Lys Asn Trp Lys Ser 20 25 30 Phe Ser Ser
Asn Cys Tyr Phe Ile Ser Thr Glu Ser Ala Ser Trp Gln 35 40 45 Asp
Ser Glu Lys Asp Cys Ala Arg Met Glu Ala His Leu Leu Val Ile 50 55
60 Asn Thr Gln Glu Glu Gln Asp Phe Ile Phe Gln Asn Leu Gln Glu Glu
65 70 75 80 6180PRTArtificialSynthetic peptide. 61Thr Lys Asp Leu
Val His Thr Thr Leu Glu Cys Val Lys Lys Asn Met 1 5 10 15 Thr Thr
Glu Glu Thr Ala Trp Ser Cys Cys Pro Lys Asn Trp Lys Pro 20 25 30
Phe Ser Ser Asn Cys Tyr Phe Ile Ser Thr Glu Ser Ala Ser Trp Gln 35
40 45 Lys Ser Glu Lys Asp Cys Ala Arg Met Glu Ala His Leu Leu Val
Ile 50 55 60 Asn Thr Arg Glu Glu Gln Asp Phe Ile Phe Gln Asn Leu
Gln Glu Glu 65 70 75 80 6277PRTArtificialSynthetic peptide. 62Ser
Ala Tyr Phe Val Gly Leu Ser Asp Pro Glu Gly Gln Arg His Trp 1 5 10
15 Gln Trp Val Asp Gln Thr Pro Tyr Asn Glu Ser Ser Thr Phe Trp His
20 25 30 Pro Arg Glu Pro Ser Asp Pro Asn Glu Arg Cys Val Val Leu
Asn Phe 35 40 45 Arg Lys Ser Pro Lys Arg Trp Gly Trp Asn Asp Val
Asn Cys Leu Gly 50 55 60 Pro Gln Arg Ser Val Cys Glu Met Met Lys
Ile His Leu 65 70 75 6377PRTArtificialSynthetic peptide. 63Ser Ala
Tyr Phe Val Gly Leu Ser Asp Pro Glu Gly Gln Arg His Trp 1 5 10 15
Gln Trp Val Asp Gln Thr Pro Tyr Asn Glu Ser Ser Thr Phe Trp His 20
25 30 Pro His Glu Pro Ser Asp Pro Asp Glu Arg Cys Val Val Leu Asn
Phe 35 40 45 Arg Lys Thr Pro Lys Arg Trp Gly Trp Asn Asp Val His
Cys Ile Val 50 55 60 Pro Gln Arg Ser Val Cys Glu Met Met Lys Ile
His Leu 65 70 75 649PRTArtificialSynthetic peptide. 64Gly Ile Leu
Gly Phe Val Phe Thr Leu 1 5
* * * * *